Gefitinib (ZD1839)

目录号：S1025

Molecular Weight(MW): 446.90

Gefitinib (ZD1839)是一种EGFR抑制剂，作用于NR6wtEGFR和NR6W细胞中的Tyr1173，Tyr992，Tyr1173和Tyr992，IC50 分别为37 nM，37nM，26 nM和57 nM。

规格

价格

库存

购买数量

10mM (in 1mL DMSO)	RMB 1574.78	现货
100mg	RMB 1227.69	现货
250mg	RMB 2205.98	现货
大包装	有超大折扣

大剂量询单有大折扣！

今日订购，明日送达，全国免运费！

全国免费电话：400-668-6834 | Email：info@selleck.cn

客户使用Selleck该产品发表文献98篇：

Nature, 2017, 547(7664):453-457

PubMed: 28678785 ( click the link to review the publication )

Nature, 2016, 534(7609):647-51

PubMed: 27338794 ( click the link to review the publication )

Nature, 2014, 508(7494):118-22

PubMed: 24670642 ( click the link to review the publication )

Nature, 2012, 483(7387):100-3

PubMed: 22281684 ( click the link to review the publication )

Cell, 2012, 151(5):937-50

PubMed: 23178117 ( click the link to review the publication )

Cancer Discov, 2015, 5(7):713-22

PubMed: 25934077 ( click the link to review the publication )

Cancer Discov, 2012, 2(10):934-47

PubMed: 22961667 ( click the link to review the publication )

Cancer Discov, 2011, 1(7):608-25

PubMed: 22586683 ( click the link to review the publication )

Cell Res, 2015, 10.1038/cr.2015.16

PubMed: 25656847 ( click the link to review the publication )

Mol Cell, 2014, 55(6):904-15

PubMed: 25219500 ( click the link to review the publication )

Hepatology, 2016, 64(2):488-500

PubMed: 27015352 ( click the link to review the publication )

Ann Oncol, 2013, 24(2):362-9

PubMed: 22967992 ( click the link to review the publication )
Nat Commun, 2015, 6:6377

PubMed: 25758528 ( click the link to review the publication )

J Thorac Oncol, 2015, 10.1097/JTO.0000000000000500

PubMed: 25658629 ( click the link to review the publication )

Clin Cancer Res, 2015, 10.1158/1078-0432.CCR-14-2789

PubMed: 25948633 ( click the link to review the publication )

Clin Cancer Res, 2015, 10.1158/1078-0432.CCR-15-0560

PubMed: 25964297 ( click the link to review the publication )

Proc Natl Acad Sci USA, 2015, 112(6):1839-44

PubMed: 25605917 ( click the link to review the publication )

Cancer Res, 2014, 74(1):253-62

PubMed: 24165158 ( click the link to review the publication )

Mol Syst Biol, 2011, 7:486

PubMed: 21525872 ( click the link to review the publication )

Cell Rep, 2015, 10.1016/j.celrep.2015.04.049

PubMed: 26027934 ( click the link to review the publication )

Cell Death Differ, 2012, 19(12):1908-16

PubMed: 22722337 ( click the link to review the publication )

Int J Cancer, 2014, 134(11):2560-71

PubMed: 24374738 ( click the link to review the publication )

Int J Cancer, 2012, 131(12):2961-9

PubMed: 22514082 ( click the link to review the publication )

Int J Cancer, 2012, 131(2):334-43

PubMed: 21858806 ( click the link to review the publication )
Oncogene, 2014, 33(19):2495-503

PubMed: 23728339 ( click the link to review the publication )

Oncogene, 2014, 33(35):4385-95

PubMed: 24096476 ( click the link to review the publication )

Oncogene, 2012, 32(34):4034-42

PubMed: 22964644 ( click the link to review the publication )

Oncogene, 2011, 30(6):737-50

PubMed: 20890302 ( click the link to review the publication )

MBio, 2014, 5(4):e01340-14

PubMed: 25096879 ( click the link to review the publication )

Cancer Lett, 2014, 342(1):82-91

PubMed: 24001610 ( click the link to review the publication )

Cancer Lett, 2012, 321(2):187-94

PubMed: 22343320 ( click the link to review the publication )

J Pathol, 2016, 239(3):320-34

PubMed: 27102572 ( click the link to review the publication )

Cell Death Dis, 2019, 10(4):283

PubMed: 30911072 ( click the link to review the publication )

J Clin Endocrinol Metab, 2013, 98(6):2502-12

PubMed: 23559083 ( click the link to review the publication )

Cell Death Dis, 2014, 5:e1445

PubMed: 25299770 ( click the link to review the publication )

Mol Cancer Ther, 2016, 10.1158/1535-7163.MCT-15-0375

PubMed: 27196768 ( click the link to review the publication )
Mol Cancer Ther, 2013, 13(2):444-53

PubMed: 24258346 ( click the link to review the publication )

Mol Cancer Ther, 2013, 12(11):2541-58

PubMed: 24026012 ( click the link to review the publication )

Mol Oncol, 2015, 9(2):527-43

PubMed: 25454348 ( click the link to review the publication )

Mol Oncol, 2014, 10.1016/j.molonc.2014.05.005

PubMed: 24908424 ( click the link to review the publication )

Mol Oncol, 2014, 9(1):260-9

PubMed: 25226813 ( click the link to review the publication )

Mol Cell Proteomics, 2015, 10.1074/mcp.M115.049783 mcp.M115.049783.

PubMed: 25953087 ( click the link to review the publication )

Carcinogenesis, 2013, 34(9):1994-9

PubMed: 23677069 ( click the link to review the publication )

Carcinogenesis, 2010, 31(11):1948-55

PubMed: 20837598 ( click the link to review the publication )

Radiother Oncol, 2013, 108(3):473-8

PubMed: 23891090 ( click the link to review the publication )

Cell Oncol , 2014, 37(5):377-86

PubMed: 25228008 ( click the link to review the publication )

Cancer Sci, 2012, 103(1):7-16

PubMed: 21951556 ( click the link to review the publication )

Antivir Res, 2011, 89(1):64-70

PubMed: 21094187 ( click the link to review the publication )
Biochim Biophys Acta, 2016, 10.1016/j.bbagen.2016.05.011

PubMed: 27180173 ( click the link to review the publication )

Antimicrob Agents Chemother, 2014, 10.1128/AAC.02393-14

PubMed: 24663025 ( click the link to review the publication )

Biochem Pharmacol, 2012, 84(4):425-31

PubMed: 22634404 ( click the link to review the publication )

J Biol Chem, 2013, 288(48):34930-42

PubMed: 24142702 ( click the link to review the publication )

Colloids and Surfaces B: Biointerfaces, 2014, 123:61-7

PubMed: 25216919 ( click the link to review the publication )

J Immunother, 2011, 34(4):372-81

PubMed: 21499124 ( click the link to review the publication )

J Chromatogr A, 2015, 10.1016/j.chroma.2015.04.055

PubMed: ( click the link to review the publication )

Int J Mol Sci, 2012, 13(9):12000-16

PubMed: 23109896 ( click the link to review the publication )

Drug Metab Dispos, 2014, 42(3):318-22

PubMed: 24335466 ( click the link to review the publication )

Drug Metab Dispos, 2014, 42(11):1851-7

PubMed: 25165131 ( click the link to review the publication )

Drug Metab Dispos, 2013, 10.1124/dmd.113.054189

PubMed: 24335466 ( click the link to review the publication )

Toxicol Appl Pharmacol, 2015, 10.1016/j.taap.2015.05.001

PubMed: 25981168 ( click the link to review the publication )
Life Sci, 2019, 224:23-32

PubMed: 30902544 ( click the link to review the publication )

Prostate, 2013, 73(13):1453-61

PubMed: 23765757 ( click the link to review the publication )

Int J Oncol, 2012, 41(3):869-75

PubMed: 22752005 ( click the link to review the publication )

Exp Cell Res, 2016, 344(2):194-200

PubMed: 27180268 ( click the link to review the publication )

Cell Cycle, 2014, 13(24):3808-17

PubMed: ( click the link to review the publication )

Cancer Res Treat, 2012, 44(3):202-9

PubMed: 23091447 ( click the link to review the publication )

Am J Physiol Renal Physiol, 2014, 307(4):F435-44

PubMed: 24990892 ( click the link to review the publication )

Eur J Pharmacol, 2017, 821:21-28

PubMed: 29277715 ( click the link to review the publication )

Oncol Rep, 2017, 37(2):1212-1218

PubMed: 27959426 ( click the link to review the publication )

Cancer Chemoth Pharm, 2014, 74(3):511-20

PubMed: 25038613 ( click the link to review the publication )

PLoS One, 2016, 11(5):e0155230

PubMed: 27153109 ( click the link to review the publication )

PLoS One, 2014, 9(4):e93651

PubMed: 24695557 ( click the link to review the publication )
PLoS One, 2014, 9(4):e95243

PubMed: 24743578 ( click the link to review the publication )

PLoS One, 2014, 9(12):e114000

PubMed: 25486409 ( click the link to review the publication )

PLoS One, 2014, 9(5):e97719

PubMed: 24874286 ( click the link to review the publication )

PLoS One, 2013, 8(12):e82625

PubMed: 24349321 ( click the link to review the publication )

PLoS One, 2012, 7(9):e42441

PubMed: 22957020 ( click the link to review the publication )

PLoS One, 2012, 7(12):e51549

PubMed: 23272116 ( click the link to review the publication )

Mol Biosyst, 2011, 7(12):3223-33

PubMed: 21956701 ( click the link to review the publication )

Horm Cancer, 2014, 289(24):17195-202

PubMed: 24778185 ( click the link to review the publication )

Exp Mol Pathol, 2014, 97(1):154-165

PubMed: 24984270 ( click the link to review the publication )

Exp Mol Pathol, 2013, 94(2):386-97

PubMed: 23399805 ( click the link to review the publication )

Exp Mol Pathol, 2011, 91(1):400-10

PubMed: 21565184 ( click the link to review the publication )

Langenbecks Arch Surg, 2014, 10.1007/s00423-014-1235-1

PubMed: 25070024 ( click the link to review the publication )
Vet Comp Oncol, 2011, 11(2):124-39

PubMed: 22235915 ( click the link to review the publication )

Evid Based Complement Alternat Med, 2013, 2013:243859

PubMed: 23533466 ( click the link to review the publication )

Pathol Oncol Res, 2015, 10.1007/s12253-015-9916-9

PubMed: 25749811 ( click the link to review the publication )

Exp Ther Med, 2019, 17(1):953-959

PubMed: 30651886 ( click the link to review the publication )

Korean J Parasitol, 2014, 52(4):439-41

PubMed: 25246725 ( click the link to review the publication )

Int J Radiat Oncol Biol Phys, 2015, 10.1016/j.ijrobp.2015.01.026

PubMed: 25823448 ( click the link to review the publication )

Int J Radiat Oncol Biol Phys, 2014, 88(4):947-54

PubMed: 24606853 ( click the link to review the publication )

University of Alberta, 2014, Yahya Muhammad Fiteih

PubMed: ( click the link to review the publication )

Guangxi Medical University, 2014, Suning Huang

PubMed: ( click the link to review the publication )

JBUON , 2014, 19(2): 466-473

PubMed: ( click the link to review the publication )

Oncotarget, 2013, 4(10):1698-1711

PubMed: 24091605 ( click the link to review the publication )

Tuberc Respir Dis, 2013, 75(3):95-103

PubMed: 24101933 ( click the link to review the publication )
Oncotarget, 2012, 2(12):1134-44

PubMed: 22193779 ( click the link to review the publication )

Int J Proteomics, 2011, 2011:215496

PubMed: 22091388 ( click the link to review the publication )

客户使用该产品的14个实验数据：

c, HCC4006 lung cancer cells that have acquired a high-mesenchymal state concomitant with becoming resistant to gefitinib (red curve) exhibit increased sensitivity to GPX4 inhibition.

Nature, 2017, 547(7664):453-457. Gefitinib (ZD1839) purchased from Selleck.

Perturbation of EGFR by its ligand EGF and gefitinib (ZD-1839 Iressat; inhibits EGFR) produces opposite responses in the predicted EGFR target genes SOCS2 and NR2E1.

Mol Syst Biol 2011 7, 486. Gefitinib (ZD1839) purchased from Selleck.
Effects of shRNA-mediated RECK depletion on EGFR signaling in MEFs. (a) Immunoblotting (IB) of the indicated proteins in wild-type MEFs transduced with the indicated shRNAs and cultured for 48 h in the presence of 0.1% dimethyl sulfoxide (DMSO; vehicle) or 1 mM gefitinib (S1025, Selleck Chemicals,Houston, TX, USA). (b) Immunoprecipitation from whole lysates of cells from panel a with an anti-phosphorylated tyrosine (pTyr) antibody. Precipitates from 500 mg protein in whole cell lysates (upper) or 20 mg protein in whole cell lysates (lower) were analyzed by IB with anti-EGFR antibody.

Oncogene 2010 30, 737-750. Gefitinib (ZD1839) purchased from Selleck.

(B–C) LNCaP (B) and LNCaP-AI (C) cells were transiently transfected with sPLA2-IIa(-800)-Luc (0.5 μg). The cells were then treated with Erlotinib (20 μM), Gefitinib (20 μM), Lapatinib (20 μM), CI-1033 (8 μM), LY294002 (20 lM) and Bortezomib (20 μM) without or with EGF (100 ng/ml) for 24 h. Luciferase assay was performed according to a standard protocol with Renilla luciferase as an internal control. Data are presented as the mean (±SD) of duplicate values of a representative experiment that was independently repeated for five times.

Carcinogenesis 2010 31, 1948–1955 . Gefitinib (ZD1839) purchased from Selleck.
LNCaP-AI cells were starved in 1% stripped medium for 24 h. The cells were then treated with Erlotinib (20 μM), Gefitinib (20 μM), Lapatinib (20 μM), CI-1033 (8 μM), LY294002 (20 μM) and Bortezomib (20 μM) for 24 h. Cell culture medium was collected from each sample and subjected to ELISA for sPLA2-IIa. The condition medium samples were diluted 10 times for ELISA. Average of duplicate samples was converted to nanogram per milliliter against standard curve. The data represent one of five repeated experiments.

Carcinogenesis 2010 31, 1948–1955. Gefitinib (ZD1839) purchased from Selleck.

Suppression of EGFR signaling by Gefitinib is dose dependent and non- toxic at millimolar concentrations.Results from plaque reduction tests of Hep2 cells infected with VACV(12.5pfu/well) treated with a serial dilution of Gefitinib (1000-0.01 m) and analyzed for (A)proliferation as indicator of cytotoxicity,(B) IC50 of plaque size inhibition, (C)dose dependent inhibition of EGFR-ERK1/2signaling and VACV proteins by Western blot analysis (pEGFR detection was obtained from a different experiment with identicals ettings) and (D)dose dependent inhibition of orthopoxvirus genome replication by real-time PCR.Untreated VACV infectedcells and uninfected cells are shown as controls in the right panel.

Antiviral Res 2010 89, 64-70. Gefitinib (ZD1839) purchased from Selleck.
A circular zone of EGFR activated but uninfected cells facilitate virus induced plaque development , efficiently blocked by Gefitinib. (A)Immun of luorescent staining of aplaque reduction tests with Hep2 cells 24,48,72 and 96 h after VACV infection (6.25pfu/chamber). VACV infected cells(green) were visualized by human IgG directed to orthopoxviruses (VIG) detected with a secondary FITC labelled antibody. Uninfected cells with activated EGFR signaling(red) are detected with a secondary Cy3labelled antibody. Positive cells for both , VACV and phosphorylated EGFR are shown in yellow(merge). Cellular nuclei are counterstained with DAPI. (B)Immunofluorescent staining of a plaque reduction test as described for (A) and treated with three different Gefitinib concentrations (1000 nM, 1 nM, and 0.01 nM) . The test was analyzed 96h afterVACV infection.Uninfected cells are shown as controls. Magnification100×.(For interpretation of the references to color in this figure legend , the reader is referred to the web version of the article.)

Antiviral Res 2010 89, 64-70. Gefitinib (ZD1839) purchased from Selleck.

Susceptibility of lung cancer cells to cytolytic activity of NK-92 cells after treatment with EGFR inhibitors. Three lung cancer cells were untreated (open circle) or treated with 10 μM erlotinib or gefitinib (black filled square or black filled triangle) for 24 hours. The lung cancer cells were cocultured with NK-92 cells at indicated effector to target ratio (E:T ratio). To determine the specificity of NKG2D-mediated cytolysis of lung cancer cells, NK-92 cells were preincubated with blocking mAb against NKG2D before the assay (gray filled square and triangle) and correspond-ing isotype mAb (open square and triangle).

J Immunother 2011 34(4), 372-81. Gefitinib (ZD1839) purchased from Selleck.
Inhibition of 5-HT-induced 5-HT3A and 5-HT3AB receptor currents.

Eur J Pharmacol, 2017, 821:21-28. Gefitinib (ZD1839) purchased from Selleck.

The EGF-dependent increased association of PCM1 and AZI1 requires EGFR kinase activity. ZD1839 (Iressa)—EGFR tyrosine kinase inhibitor.

Mol Biosyst 2011 7, 3223-33. Gefitinib (ZD1839) purchased from Selleck.
Reduction of GPER expression in HCC1806 cells after treatment with gefitinib. (A) Concentration dependence. HCC1806 cells were treated with 50-500 nM gefitinib for 48 h. GPER was detected by western blotting. (B) Time dependence. HCC1806 cells were treated with 200 nM gefitinib for 24-96 h. ^ap<0.05 vs. control; ^bp<0.001 vs. control. Mean values and SE of three independent experiments are shown. (C) Representative western blotting of concentration dependence. (D) Representative western blotting of time dependence

Oncol Rep, 2017, 37(2):1212-1218. Gefitinib (ZD1839) purchased from Selleck.

Inhibition of signaling pathway activation in lung tumor cell lines by kinase inhibitors. Lung tumor cells were cultured in 10% FBS until reaching ∼80% confluence and then the cells were starved in serum-free medium for overnight, followed by 4-hour treatment with the inhibitors. Cell lysates were then prepared and used for determination of the pathway activation signals by the CEER assay.

Int J Proteomics 2011 215496. Gefitinib (ZD1839) purchased from Selleck.
Breast cancer cells were pretreated with 100ng/ml EGF for 15 min and then treated with the indicated concentrations of Gefitinib for 24 hours.

2010 Dr. Zhang of Tianjin Medical University. Gefitinib (ZD1839) purchased from Selleck.

MTT assay result. 0-500nM Gefitinib treated with H1299, H358, H25 and HCC827 cell lines by 72h, Proliferation rate was tested.

2010 Dr. Vicky Tin from University of Hong Kong. Gefitinib (ZD1839) purchased from Selleck.

产品安全说明书

EGFR抑制剂选择性比较

生物活性

产品描述

Gefitinib (ZD1839)是一种EGFR抑制剂，作用于NR6wtEGFR和NR6W细胞中的Tyr1173，Tyr992，Tyr1173和Tyr992，IC50 分别为37 nM，37nM，26 nM和57 nM。

特性

Gefitinib是有效的EGFR酪氨酸激酶抑制剂。

靶点

Tyr1173 (NR6W cells) ^[1]	Tyr1173 (NR6wtEGFR cells) ^[1]	Tyr992 (NR6wtEGFR cells) ^[1]	Tyr992 (NR6W cells) ^[1]
26 nM	37 nM	37 nM	57 nM

体外研究

Gefitinib 作用于高和低表达EGFR的细胞系，包括NR6, NR6M 和 NR6W 细胞系，有效抑制EGFR上全部酪氨酸磷酸化位点。磷酸化位点 Tyr1173和Tyr992敏感性较低，需要高浓度Gefitinib才能抑制。Gefitinib作用于NR6W细胞，高效阻断PLC-γ磷酸化, IC50为27nM。NR6wtEGFR 和NR6M细胞系具有低水平PLC-γ磷酸化， IC50 分别为 43 nM和 369 nM。Gefitinib抑制AKT磷酸化，作用于低EGFR和EGFRvIII表达的细胞系， IC50 分别为220 和263nM。Gefitinib按 0.1 到 0.5μM剂量处理，显著促进而不是废除 NR6M细胞形成集落。然而, 2μM Gefitinib 完全抑制 NR6M 集落形成。Gefitinib 作用于高和低EGFR表达的细胞系，EGF 刺激72小时后，快速抑制EGFR 和ERK 磷酸化，这种作用存在剂量依赖性。^[1]Gefitinib抑制 EGF驱动的未转化MCF10A 细胞生长，IC50为 20 nM。^[2] Gefitinib 作用于MDA-MB-231细胞，抑制EGF信号。Gefitinib严重抑制细胞数的增多，这种作用存在剂量依赖性。 ^[3]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID
KB	M1nNXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXTJR\|UxRTBwMEW0JO69VQ>?	MVyxOlUyPjR5Mx?=
NIH3T3	NETBWI5HfW6ldHnvckBCe3OjeR?=	MXKwMlIh\|ryP	M3uyUVIhcA>?	MnjoSG1UVw>?	MkDhTY5pcWKrdHnvckBw\iCHR1[gd5RqdXWuYYTl[EBpfW2jbjDldoJDOSCjdYTvdIhwe3Cqb4L5cIF1cW:wIIfpeIghUUN3MDDv[kAxNjBzNESg{txO	NUHrd5JPOTZ2OECyPFQ>
COS7	MVvGeY5kfGmxbjDBd5NigQ>?	MXS5OkDPxE1?			MU\Jcohq[mm2aX;uJI9nKGi3bXHuJGpCUzJiVk[xO2YhdXW2YX70JIV5eHKnc4Pl[C=>	NFrEfJcyPzF5OEeyNi=>
A549	NH3aWohEgXSxdH;4bYMhSXO\|YYm=		M2O5O\|k3KGh?	MXPEUXNQ	MkCyTWM2OD1zMz61PUDPxE1?	Ml\QNVg{OTN6MEe=
K562	NV72U5RwS3m2b4TvfIlkKEG\|c3H5		MWe5OkBp	MmfBSG1UVw>?	M{Xmb2lEPTB;OT6zOkDPxE1?	NGH5fJUyQDNzM{iwOy=>
MDA-MB-231	MU\DfZRwfG:6aXOgRZN{[Xl?		MUm5OkBp	NInVNYpFVVOR	NWKzZYh1UUN3ME2zOk43OSEQvF2=	NHXJVZMyQDNzM{iwOy=>
MOLT4	NUG0U3pES3m2b4TvfIlkKEG\|c3H5		NWDlTXg1QTZiaB?=	M1rnSmROW09?	NF;rT2xKSzVyPUG1MlAzKM7:TR?=	MknWNVg{OTN6MEe=
MCF7	Mkn6R5l1d3SxeHnjJGF{e2G7	NEP5Tos2OCEQvF2=	MUe3NkBp		Mk\uTWM2OD1zMj6wOUDPxE1?	M1OwdVE5PzdzOEG5
BT474	M1XScGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		M1jCeVczKGh?		M17sT2FvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iQmS0O\|Qh[2WubIOgc5ZmemW6cILld5NqdmdiRWLCZlIhf2m2aDDFR\|UxKG:oIECuN{DPxE1?	MYKxPVAzQDR{NB?=
HN5	NUjYd5cyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		M4L3XFczKGh?		MXvBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEiQNTDj[YxteyCxdnXy[ZhxemW\|c3nu[{BGT0[UIIfpeIghTUN3MDDv[kAxNjBzIN88US=>	NFXtO3QyQTB{OESyOC=>
BA/F3	MnzpR5l1d3SxeHnjJGF{e2G7		MXq3NkBp		NYjzW48xS3m2b4TvfIlkcXS7IHHnZYlve3RibX;1d4UhSkFxRkOgZ4VtdHNiZYjwdoV{e2mwZzDFS2ZTKEx6NUjSJI12fGGwdDD3bZRpKEmFNUCgc4YhOC5yMUC4JO69VQ>?	M4izOlE6OjN7MkK5
NIH3T3	M2rqOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NYL0UJRPPzJiaB?=		MknSS5Jwf3SqIHnubIljcXSrb36gc4YhdW:3c3WgUmlJNzOWMzDj[YxteyCneIDy[ZN{cW6pIHXyRlIh\2WwZTD3bZRpKEmFNUCgc4YhOC53NDFOwG0>	Mk\wNVk3PjV\|N{e=
MCF7 MX	Mnu5SpVv[3Srb36gRZN{[Xl?		MXKzNEBucW5?		M37weGlvcGmkaYTpc44hd2ZiQlPSVEBmgHC{ZYPz[YQhf2m2aDDJR\|UxKG:oIEGuNUDPxE1?	NF\wSJoyQTl\|Mkm2NC=>
A431	NUnMU5NST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGrZfYYyOCEQvF2=	NV7Eb\|JpPzJiaB?=		NWXKXGgyT0l3ME2wMlUyPCEQvF2=	MXSxPVk3QTR4NR?=
A431	NVXNd2N5U2mwYYPlJGF{e2G7	M{fsNFAvOSEQvF2=	Ml;YNUBp		MXTJcohq[mm2aX;uJI9nKEWJRj3pcoR2[2WmIFXHSnIheGixc4Doc5J6dGG2aX;u	NEiyU4gyQTl4OUS2OS=>
A431	NXvOXFZkU2mwYYPlJGF{e2G7	MXWxNFAh\|ryP	MnrFNVAhdWmw		MmLwVJJwdG:wZ3XkJIlvcGmkaYTvdpkh[WO2aY\peJkhd2ZiRVfGMYlv\HWlZXSgSWdHWiCyaH;zdIhwenmuYYTpc44>	MXOxPVk3QTR4NR?=
Sf9	M3nURWtqdmG\|ZTDBd5NigQ>?		NYf4bIR5OTBibXnu	M1u5XWROW09?	M1q3b2lvcGmkaYTpc44hd2ZiRVfGVkBmgHC{ZYPz[YQh[XO\|ZYPz[YQh[XNiaX7obYJqfGmxbjDv[kBz\WOncITvdkBifXSxcHjvd5Bpd3K7bHH0bY9vKHerdHigTWM2OCCxZjCwMlA{OyEQvF2=	NU\kTXQ{OjByNU[0NlU>
NCI-H1975	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NED2U5Q2KM7:TR?=	NXPnfIk2PzJiaB?=		M1\mUWlEPTB;OD6yOkDPxE1?	NVT1SlQ5OjBzNUG2O\|A>
NCI-H1975	NH3odFBMcW6jc3WgRZN{[Xl?	NYP0dJhJOTBizszN			NEnXWmdKdmirYnn0bY9vKG:oIFXHSnIh[XW2b4Doc5NxcG:{eXzheIlwdg>?	MXSyNFE2OTZ5MB?=
NCI-H1975	MY\GeY5kfGmxbjDBd5NigQ>?	MX:xNEDPxE1?			MnzkTY5pcWKrdHnvckBw\iCHUlLCNkBifXSxcHjvd5Bpd3K7bHH0bY9v	Ml\xNlAyPTF4N{C=
NCI-H1975	NFvzc41HfW6ldHnvckBCe3OjeR?=	Mnn5OUDPxE1?	NVXidHpSPDhiaB?=		NWi5PGpIUW6mdXP0bY9vKG:oIHHwc5B1d3OrczDhd5Nme3OnZDDhd{Bi[3SrdnH0bY9vKG:oIHPhd5Bie2VvMx?=	MV:yNFE2OTZ5MB?=
A375	M4nzd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7		M2f4TFQ5KGh?		MYjJR\|UxRTJyLkW1JO69VQ>?	NIrkWXQzODNyNEWzOy=>
SMMC7721	MkL1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MVi0PEBp		MX7JR\|UxRTN\|LkGyJO69VQ>?	MmXKNlA{ODR3M{e=
DU145	NYLFRXRyS3m2b4TvfIlkKEG\|c3H5		M1LhXFUh\A>?	NVLSd\|RWTE2VTx?=	MmLRTWM2OD12Mj6xO{DPxE1?	NEDtXJMzODR4NkW1OS=>
MIAPaCa2	NVTre5ZJS3m2b4TvfIlkKEG\|c3H5		M{Py[lUh\A>?	M2frfGROW09?	NIDpXWhKSzVyPUWwMlYzKM7:TR?=	MWKyNFQ3PjV3NR?=
PANC1	NVTmXG5bS3m2b4TvfIlkKEG\|c3H5		M1vRVlUh\A>?	M{OydmROW09?	NXTJbGw1UUN3ME20NE41OiEQvF2=	MoXMNlA1PjZ3NUW=
PC9	NFXUVldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlK3RY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDFS2ZTNWSnZnnjbYVvfCCqdX3hckBRSzliY3XscJMhf2m2aDDFR\|UxKG:oIECuNFE4KM7:TR?=	NHS1SYkzOTJyOEiwNi=>
PC9	M37YO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MkjJRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDndo94fGhvcnXzbZN1[W62IHj1cYFvKFCFOTDj[YxteyCneIDy[ZN{cW6pIFXHSnIhTTd2Nm;BO\|UxN1R5OUDNJI12fGGwdDD3bZRpKEWFNUCgc4YhPyEQvF2=	NEfu[2gzOTJyOEiwNi=>
PC3	NUfaUpUxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NX3yU3hzOTBizszN	MX:3NkBp	NW\ibXF[TE2VTx?=	NWLkbYR{UUN3ME23MlQh\|ryP	MnTWNlE{PTN3NE[=
MDA-MB-468	NH:0fXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWqxNFAh\|ryP	NWjrS2lPPDhiaB?=	NIP6PGlFVVOR	MVjBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eR?=	NWKwOVVSOjF2Mkm2N\|I>
Plasmodium falciparum					NWPSd25QeUiWUzDwdo9ncWyrbneg[o9zKGmwaHnibZRwenNib3[gVIxie22xZHn1cUBn[WylaYDhdpVuKHC{b3zp[oVz[XSrb36=	M3XPVlIyQDF5MES1
NCI-H1993	M4LLWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NGnYZ4c4OiCq	NY\VPVR4TE2VTx?=	MoWxTWM2OD1yLkGg{txO	MUKyNVkyPjR\|Mx?=
NCI-H292	NX;1bHJvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		M1;TTlczKGh?	MV\EUXNQ	NUHsU5JYUUN3ME2wMlAzKM7:TR?=	MXmyNVkyPjR\|Mx?=
A431	MXPLbY5ie2ViQYPzZZk>		MYKyJIg>	NI[5NndFVVOR	M{HvOWlvcGmkaYTpc44hd2ZiRVfGVkBxcG:\|cHjvdplt[XSrb36gbY4hTUeILYP0bY12dGG2ZXSgbJVu[W5iQUSzNUB4cXSqIFnDOVAhd2ZiMD6wNFEh\|ryP	NIH0NnozOjFyMUGzNi=>
MCF7	NGHNc\|lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFrYNW8yODEEoN88[{9uVA>?	NHjPWm01QCCq	M3n5bWROW09?	NHTLVGNCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIF3DSlch[2WubIOgc5ZmemW6cILld5NqdmdiRVfGVkBo\W6nIIfpeIghUUN3MDDv[kAyOi5yNTFOwG0>	MlG4NlIyOTlzM{C=
BT474	M3XqSGN6fG:2b4jpZ{BCe3OjeR?=	NXrZUHV[OTBizszN	NXfrenRXPDhiaB?=		MYrDfZRwfG:6aXPpeJkh[WejaX7zeEB{\XK3bT3zeIFzfmWmIHj1cYFvKEKWNEe0JINmdGy\|	MXyyNlE{QDNyOB?=
MCF7	MlnHR5l1d3SxeHnjJGF{e2G7	NYjOOYt{OTBizszN	MWW0PEBp		M320WWN6fG:2b4jpZ4l1gSCjZ3HpcpN1KHOncoXtMZN1[XK4ZXSgbJVu[W5iTVPGO{Bk\WyuczDveoVzNWW6cILld5NqdmdiRYLiRlIh[2WubIO=	MWCyNlE{QDNyOB?=
HCC827	M1XKd2tqdmG\|ZTDBd5NigQ>?	NGrSd3ExNjF{NTFOwG0>	NGmwdFAzPCCq	NYHOfZVmTE2VTx?=	M4HCc2lvcGmkaYTpc44hd2ZiRVfGVkBl\WxiRUe0Ok1CPzVyIH31eIFvfCC\MUC2PEBifXSxcHjvd5Bpd3K7bHH0bY9v	MWGyNlM{QTN2Mh?=
HCC827	MmPwT4lv[XOnIFHzd4F6	NUL5UmxJOC5zMkWg{txO	M1XoW\|I1KGh?	MXrEUXNQ	MYfJcohq[mm2aX;uJI9nKEWJRmKg[IVtKEV5NE[tRVc2OCCvdYThcpQudWWmaXH0[YQhTXKtIIDoc5NxcG:{eXzheIlwdg>?	NWPWR5JCOjJ\|M{mzOFI>
HCC827	MX;LbY5ie2ViQYPzZZk>	MUmwMlEzPSEQvF2=	MYGyOEBp	MmjhSG1UVw>?	NYL1SnFIUW6qaXLpeIlwdiCxZjDFS2ZTKGSnbDDFO\|Q3NUF5NUCgcZV1[W62LX3l[IlifGWmIFHreEBxcG:\|cHjvdplt[XSrb36=	NVn6WpBkOjJ\|M{mzOFI>
A431	NH7JV41McW6jc3WgRZN{[Xl?	MX2xNFAh\|ryP	NFP3SGI{OCCvaX6=		NHjyfGxKdmirYnn0bY9vKG:oIFXHSnIh\GW{aY\l[EBnem:vIHj1cYFvKEF2M{GgZ4VtdCCvZX3idoFv\SCjc4Pld5Nm\CCjczDpcohq[mm2aX;uJI9nKHCxbImtS4x2NVS7cjDwbI9{eGixconsZZRqd25id3n0bEBKSzVyIH;mJFEvODhizszN	NIfCdGwzOjZ7OEe4Ni=>
H460	M{jGNmN6fG:2b4jpZ{BCe3OjeR?=		M3XDU\|czKGh?		NV;rTHY6UUN3ME21MlU6KM7:TR?=	M4\UcFIzPzJ5NES5
HT-29	M1z2NGN6fG:2b4jpZ{BCe3OjeR?=		MX63NkBp		NHjpbJNKSzVyPUOuN\|Yh\|ryP	NHO2Z3czOjd{N{S0PS=>
SGC7901	MlPTR5l1d3SxeHnjJGF{e2G7		MYm3NkBp		M3LBcGlEPTB;MUCuNlYh\|ryP	MkXPNlI4Ojd2NEm=
A498	NHrWOIdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmSyRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCDNEm4JINmdGy\|IHX4dJJme3OrbnegSWdHWiCjbnSgV3JEKHerdHigTWM2OCCxZjC4MlYh\|ryP	MVSyNlgyQDh2OB?=
Calu3	NVXkeIE{S3m2b4TvfIlkKEG\|c3H5	MWCxNEDPxGdxbVy=	NFLmRlY4OiCq		M{TjbmlEPTB;MT62JO69VQ>?	NVGzWmFlOjNzMU[xOlg>
FADU	M2Tje2N6fG:2b4jpZ{BCe3OjeR?=	M2XCdlExKM7:Zz;tUC=>	M3LPR\|czKGh?		NWrjWJNJUUN3ME2wMlA2KM7:TR?=	M3P5PVI{OTF4MU[4
HCC827	MknXR5l1d3SxeHnjJGF{e2G7	MnLwNVAh\|rypL33M	M2DWUlczKGh?		MnHlTWM2OD1yLkCwNVUh\|ryP	NYLnZpozOjNzMU[xOlg>
PC9	NIrFNGFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUOxNEDPxGdxbVy=	NUjofVJ2PzJiaB?=		NXzjR4U2UUN3ME2wMlAyPCEQvF2=	MX[yN\|EyPjF4OB?=
Sf9	MWnLbY5ie2ViQYPzZZk>		M1:0WVEhcA>?	MYXEUXNQ	MUTJcohq[mm2aX;uJI9nKGi3bXHuJGdUXC22YXfn[YQhTUeIUjDMPFM1WiCvdYThcpQh\XiycnXzd4VlKHerdHigTWM2OCCxZjCwMlAyPSEQvF2=	M4nPWFI{PjFzNkmx
16HBE14o-	MlXOR5l1d3SxeHnjJGF{e2G7	M2nWN\|ExKM7:TR?=	MlLVO\|IhcA>?	NHj6OWRFVVOR	M{DI[GN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJFE3UEKHMUTvMUBk\WyuczDoZZJjd3Krbnege4lt\CC2eYDlJGVITlJiYYPz[ZN{\WRiYYOg[5Jwf3SqIHnubIljcXSrb36ge4l1cCCLQ{WwJI9nKDF{LkexJO69VQ>?	MorVNlM3Pjh2NEG=
NCI-H1975	NXvEWYU{S3m2b4TvfIlkKEG\|c3H5	NGDQWpcyOCEQvF2=	NXTFXWVJPzJiaB?=	NUfBVXZsTE2VTx?=	MWfDfZRwfG:6aXPpeJkh[WejaX7zeEBo\W[rdHnubYIuemW\|aYP0ZY51KGi3bXHuJG5EUS2KMUm3OUBk\WyuczDoZZJjd3KrbnegSWdHWiCOOEW4Vk9VPzlyTTDkc5VjdGVibYX0ZY51KGG\|c3Xzd4VlKGG\|IHfyc5d1cCCrbnjpZol1cW:wIIfpeIghUUN3MDDv[kA3NjlzNzFOwG0>	MUmyN\|Y3QDR2MR?=
16HBE	MlvSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NEXDVnE4OiCq	Mn;lSG1UVw>?	MYPBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKDF4SFLFJINmdGy\|IHX4dJJme3Orbnege4lt\CC2eYDlJGVITlJid3n0bEBKSzVyIH;mJFEvPjBzIN88US=>	NIH6eoUzOzd7MkOxPC=>
16HBE	MULGeY5kfGmxbjDBd5NigQ>?	NYjYXGU1OTByIN88US=>	Ml7ZNVUxKG2rbh?=	M{H2VWROW09?	MYTJcoR2[3Srb36gc4Yhdmm2cnnjJI95cWSnIIDyc4R2[3Srb36gbY4hcHWvYX6gNVZJSkViY3XscJMh\XiycnXzd4lv\yC5aXzkJJR6eGViRVfGVi=>	M4rufVI{Pzl{M{G4
A549	NXW3VlVMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NYS0fIkxPzJiaB?=	M4DyfGROW09?	NWnmdII{SW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEB4cWymIIT5dIUhTUeIUj;rMXJieyCmZYDlcoRmdnRiaIXtZY4hSTV2OTDj[YxteyC5aYToJGlEPTBib3[gOE43OjZizszN	NUHPeXZQOjN5OUKzNVg>
SH-SY5Y	NXzjZXdkS3m2b4TvfIlkKEG\|c3H5		M4T6SlczKGh?		Mn3STWM2OD1zOD6yNUDPxE1?	NXHwfpdHOjN6N{G5NFk>
LoVo	M3XGT2tqdmG\|ZTDBd5NigQ>?		M2LMNVIhKGh?	MmizSG1UVw>?	NVrh[GNKUW6qaXLpeIlwdiCxZjDFS2ZTKHCqb4PwbI9zgWyjdHnvckB4cXSqIFnDOVAhd2ZiMD6wOlIh\|ryP	NHrQNHQzOzl\|MEm5OC=>
PC9	NX3rV3BsU2mwYYPlJGF{e2G7		MlPMNkBp	MU\EUXNQ	NYjIRVAzUW6qaXLpeIlwdiCxZjDFS2ZTKGW6b36gNVkh\GWuZYTpc44h[WO2aY\heIlv\yCvdYThcpQheGixc4Doc5J6dGG2aX;uJIlvKGi3bXHuJHBEQSClZXzsd{B4cXSqIFnDOVAhd2ZiMD6wNFg4KM7:TR?=	NHv4VI8zOzl\|MEm5OC=>
HCC827	M37Demdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NVTzS3FyPzJiaB?=		MVTJR\|UxRTBwMEGyJO69VQ>?	Mon3NlM6PzNzNki=
A549	NYHaV5V3U2mwYYPlJGF{e2G7	NYDjXlZtOSEQvF2=	MUmxJIg>	MYrEUXNQ	NFXN[3NKdmirYnn0bY9vKG:oIFXHSnIh[XW2b4Doc5NxcG:{eXzheIlwdiC5aYToJGlEPTBib3[gNE4xOzl7IN88US=>	M{\uWlI{QTh6M{W0
A549	NF7qTYtHfW6ldHnvckBCe3OjeR?=	MU[xJO69VQ>?	M2P6[FEhcA>?	NVLiS3RjTE2VTx?=	NIPQZ2pE\WyudXzhdkB2eHSja3W=	M{X4Z\|I{QTh6M{W0
HCC827	NGLkTYFMcW6jc3WgRZN{[Xl?	MVSwMlUh\|ryP	MlnXNkBp	M{S0UWROW09?	M2LpS2lvcGmkaYTpc44hd2ZiRVfGVkBxcG:\|cHjvdplt[XSrb36gbY4h\2WoaYTpcoljNXKnc3nzeIFvfCCqdX3hckBJS0N6MkegZ4VtdHN?	M4nyUFI{QTl\|M{K4
HCC827	NEntc\|RHfW6ldHnvckBCe3OjeR?=	MkfwNE42KM7:TR?=	NGLZR\|czKGh?	MVPEUXNQ	M1e3bGlvcGmkaYTpc44hd2ZiYz3N[ZQheGixc4Doc5J6dGG2aX;uJIlvKGenZnn0bY5q[i2{ZYPpd5RidnRiaIXtZY4hUEOFOEK3JINmdGy\|	M{\kT\|I{QTl\|M{K4
HCC827	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVmxNEDPxE1?	NH3IcIg4OiCq	NVraZW9{TE2VTx?=	M{PzRWFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4Sg[4VncXSrbnniMZNmdnOrdHn2[UBpfW2jbjDIR2M5OjdiY3XscJMhcGG{Yn;ybY5oKEWJRmKgSVc1PiC2bzDBO\|UxKGSnbHX0bY9vKHerdHigTWM2OCCxZjCwMlAxPThzIN88US=>	MXKyOFA2OzZ5NB?=
A431	MkXzT4lv[XOnIFHzd4F6	MYWxNFAh\|ryP	MVezNEBucW5?		NGHkS5ZKdmirYnn0bY9vKG:oIFXHSnIhcW5ic3jl[EBu\W2kcnHu[UB3\XOrY3zld{B4cXSqIFnDOVAhd2ZiMT6xJO69VQ>?	NFnZcnUzPDB7NESzNi=>
BCRP-MDCK2	MVLGeY5kfGmxbjDBd5NigQ>?	NUmySFJUOS56IN88US=>	MYq3NkBp	NV3N[2ZzTE2VTx?=	NE\RNG9KdmO{ZXHz[UBw\iCybHHzcYEhdWWvYoLhcoUh\XiycnXzd4lwdiCxZjDCR3JRKGW6cILld5NqdmdicnXwc5J1\XJiZ3Xu[UBITlB?	MkftNlQyQDR{MUO=
BCRP-MDCK2	M4PPTGZ2dmO2aX;uJGF{e2G7	NWjkXpk2OS56IN88US=>	NXTBSHJxPzJiaB?=	MlvvSG1UVw>?	NYnWWYlrWmWmdXP0bY9vKG:oIIDsZZNu[SCvZX3idoFv\SCneIDy[ZN{cW:wIH;mJGJEWlBiZYjwdoV{e2mwZzDy[ZBwenSncjDn[Y5mKEeIUB?=	MVWyOFE5PDJzMx?=
MDCK	NYjJRnZwS3m2b4TvfIlkKEG\|c3H5		MVm3NkBp	NUDKZoNlTE2VTx?=	NEC1[lZIUTVyPUGuOFUh\|ryP	MojvNlQyQDR{MUO=
MDCK2	NGnreWNHfW6ldHnvckBCe3OjeR?=	MV[xMlgh\|ryP	MoT3O\|IhcA>?	NEH6UGlFVVOR	M{TlfGlvcGmkaYTpc44hd2ZiaIXtZY4hSkOUUDDlfJBz\XO\|ZXSgZZN{\XO\|ZXSgZZMhUG:nY3jzeEA{OzN2MjDhZ4N2dXWuYYTpc44hf2m2aDDJR\|UxKG:oIEOuNVkh\|ryP	Ml6zNlQyQDR{MUO=
A431	MXLDfZRwfG:6aXOgRZN{[Xl?		NGrXXJA4OiCq	MWTEUXNQ	MVTDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDBOFMyKGOnbHzzJIV5eHKnc4PpcochTUeIUjD3bZRpKEmFNUCgc4YhOC53NTFOwG0>	M4HtZlI1PDFzMUKz
Calu3	MmmyR5l1d3SxeHnjJGF{e2G7		MoPSO\|IhcA>?	NIjURVBFVVOR	NFu1VmZEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBE[Wy3MzDj[YxteyCneIDy[ZN{cW6pIFjFVlIhf2m2aDDJR\|UxKG:oIECuPVkh\|ryP	M2n4c\|I1PDFzMUKz
KB	NIHOTVNMcW6jc3WgRZN{[Xl?	M1n4UFExKM7:TR?=	M4j5bFEhcA>?	NIHpdmRFVVOR	NUfRdVV3UW6qaXLpeIlwdiCxZjDFS2Yue3SrbYXsZZRm\CCjdYTvdIhwe3Cqb4L5cIF1cW:wIH;mJGVITlJid3n0bEBKSzVyIH;mJFAvODJ3IN88US=>	NV3rNog3OjR2MUGxNlM>
BEAS2B	NXLnd\|hQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYW1NEDPxE1?	NWfPcFJUPzJiaB?=	NYXLT41GTE2VTx?=	Ml7STWM2OD1zMz65OEDPxE1?	MV:yOFYxPzV7MR?=
NCI-H1975	MXfGeY5kfGmxbjDBd5NigQ>?	M{DTVFExOCEQvF2=	MVWxOVAhdWmw	NH3LU41FVVOR	M2TpVmlv\HWldHnvckBw\iCQTzDwdo9lfWO2aX;uJIlvKGi3bXHuJG5EUS2KMUm3OUBk\WyuczDoZZJjd3KrbnegSWdHWiCOOEW4Vk9VPzlyTTDteZRidnR?	MlzhNlQ3ODd3OUG=
Hela	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		M{DYbVI1KGh?	NVTLeZZPTE2VTx?=	MoDpTWM2OD1{Lk[3JO69VQ>?	NUHrSIY5OjR5M{GyPFE>
HepG2	MmjUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NWG0PGhtOjRiaB?=	NYTq[JBITE2VTx?=	NXPwUZZ7UUN3ME22MlQzKM7:TR?=	M1TEfFI1PzNzMkix
Sf9	M2HDRWtqdmG\|ZTDBd5NigQ>?		NGXJUIwyOCCvaX6=	M2rFc2ROW09?	Ml7JTY5pcWKrdHnvckBw\iCjdYTvdIhwe3Cqb4L5cIF1cW:wIH;mJJJm[2:vYnnuZY51KGircz30ZYdo\WRiRVfGVkAp[W2rbn:gZYNq\CB4NEWtNVE5PiliZYjwdoV{e2WmIIfpeIghUUN3MDDv[kAxNjB{IN88US=>	NUD2fWVXOjR5M{GyPFE>
SW620	MUXDfZRwfG:6aXOgRZN{[Xl?		MX20PEBp	NUC2OY9yTE2VTx?=	NFzTTFRKSzVyPUK4MlIh\|ryP	MmfSNlQ6ODB3OUS=
HCC827	M4GwRWZ2dmO2aX;uJGF{e2G7	MV2wMlUh\|ryP	NETTeoszKGh?	MVHEUXNQ	MoDv[I9meyCwb4SgbY5pcWKrdDDjMW1mfCCjc4Pld5Nm\CCjczDpcohq[mm2aX;uJI9nKEGNVDDwbI9{eGixconsZZRqd25?	NX7rbJNQOjN7OUOzNlg>
HCC827	M{\v[2Z2dmO2aX;uJGF{e2G7	M{m3UlAvPSEQvF2=	M{jaSVIhcA>?	NYS5cIxGTE2VTx?=	M4PYNYRw\XNibn;0JIlvcGmkaYSgZ{1O\XRiYYPz[ZN{\WRiYYOgbY5pcWKrdHnvckBw\iCyNESvOFIheGixc4Doc5J6dGG2aX;u	M3\DSVI{QTl\|M{K4
HCC827	MnL0R5l1d3SxeHnjJGF{e2G7	M2XCTVAvPSEQvF2=	NG\RO3M4OiCq	Mm\MSG1UVw>?	M2Kz[YhieyCwbzDjfZRwfG:6aXPpeJk>	NFPHPHYzOzl7M{OyPC=>
NCI-H1975	M4HibmZ2dmO2aX;uJGF{e2G7	NEjidHMyOCEQvF2=	MlGxPEBp	M2LkSmROW09?	MnXI[I9meyCwb4SgbY5pcWKrdHmgSWdHWiCjc4Pld5Nm\CCjczDy[YR2[3Srb36gbY4hTVKNIIDoc5NxcG:{eXzheIlwdg>?	M3jjXVI{OTF4MU[4
A431	MX7LbY5ie2ViQYPzZZk>	MXexJO69VQ>?	M4\y[FEhcA>?	NX7ySVZsTE2VTx?=	NEPIcXdp[XNibn:gbZJz\X[ncoPpZoxmKGmwaHnibZRqd25ib3[gSWdHWiCjdYTvdIhwe3Cqb4L5cIF1cW:w	NWDuSWU{OjR7MEC1PVQ>
LNCaP	M1H5SWZ2dmO2aX;uJGF{e2G7	NFiwcJQyOCEQvF2=	NF:zb\|MzcCCxcjC0JIg>	NI\E[VJFVVOR	NV3BVWFP\G:nczDuc5QhcW6qaXLpeEBifXSxcHjvd5Bpd3K7bHH0bY9vKG:oIHntcZVvd3C3cnnmbYVlKG[uYXeteIFo\2WmIFLtfEBie3Onc4Pl[EBieyCrbnPvdpBwemG2aX;uJI9nKFt\|MmDdRXRR	NXLSVnJjOTh4NkezNVI>
H1975	NYLtdmd2U2mwYYPlJGF{e2G7	MoHDNUDPxE1?	NGTJZnkzPCCq	NH7rO4pFVVOR	M{\DcYRw\XNibn;0JIlvcGmkaYSgSWdHWiCyaH;zdIhwenmuYYTpc44hcW5iaIXtZY4hUDF7N{WgZ4VtdHNiaHHyZo9zcW6pIFXHSnIhVDh3OGKvWFc6OE1ibYX0ZY51	NWrtR\|VxOjR4MEe1PVE>
H1975	M3HK[GZ2dmO2aX;uJGF{e2G7	MkCzNUDPxE1?	MnPONlQhcA>?	NYTpPJVNTE2VTx?=	Mk\i[I9meyCwb4SgbY5pcWKrdDDFVmsheGixc4Doc5J6dGG2aX;uJIlvKGi3bXHuJGgyQTd3IHPlcIx{KGijcnLvdolv\yCHR1\SJGw5PTiUL2S3PVBO	NWr3cG1ROjR4MEe1PVE>
HCC827	NVm5RYI6U2mwYYPlJGF{e2G7	NYfNOGVtOC5zMTFOwG0>	NVzHU\|dbOSCq	NIrLbHFFVVOR	MmGybIF{KG6xIHnydoV3\XK\|aXLs[UBqdmirYnn0bY9vKG:oIFXHSnIh[XO\|ZYPz[YQh[XNicnXjc5Zmenlib3[gSWdHWiCjdYTvdIhwe3Cqb4L5cIF1cW:w	MoqwNlQyOjR6OUi=
H1975	NHH0R2FMcW6jc3WgRZN{[Xl?	MmPlNE4{OyEQvF2=	NEC5[pMzKGh?	M{[1OWROW09?	MYHkc4V{KG6xdDDpcohq[mm2IFXHSnIhVDh3OGKvWFc6OE1iZH;1ZoxmKG23dHHueEBie3Onc4Pl[EBieyC{ZXT1Z5Rqd25iaX6gRWtVKHCqb4PwbI9zgWyjdHnvci=>	M{jFSFI1OTJ2OEm4
H1975	MXrLbY5ie2ViQYPzZZk>	MnrwNE4{OyEQvF2=	NHToWVczKGh?	NXzDXHJOTE2VTx?=	NVLUU\|k3\G:nczDuc5QhcW6qaXLpeEBGT0[UIFy4OVhTN1R5OUDNJIRwfWKuZTDteZRidnRiYYPz[ZN{\WRiYYOgdoVlfWO2aX;uJIlvKEWUSzDwbI9{eGixconsZZRqd25?	MWKyOFEzPDh7OB?=
H1975	NX7iPYZWU2mwYYPlJGF{e2G7	MUWwMlM{KM7:TR?=	NXHOfZE{OiCq	MnXOSG1UVw>?	MUTkc4V{KG6xdDDpcohq[mm2IFXHSnIhVDh3OGKvWFc6OE1iZH;1ZoxmKG23dHHueEBxcG:\|cHjvdplt[XSrb36=	M1XZOlI1OTJ2OEm4
H1975	MVLLbY5ie2ViQYPzZZk>	M165N\|AvOTJ3IN88US=>	M3XHO\|I1KGh?	NXvxZXQyTE2VTx?=	NUjJV5NS\G:nczDuc5QhcW6qaXLpeEBGT0[UIFy4OVhTN1R5OUDNJI12fGGwdDDZNVA3QCCjdYTvdIhwe3Cqb4L5cIF1cW:w	MWeyNlM{QTN2Mh?=
H1975	MnP6T4lv[XOnIFHzd4F6	MnzVNE42KM7:TR?=	MY[yOEBp	NEmze2FFVVOR	MmjR[I9meyCwb4SgbY5pcWKrdDDFS2ZTKEx6NUjSM3Q4QTCPIH31eIFvfC2vZXTpZZRm\CCHcnugdIhwe3Cqb4L5cIF1cW:w	MmfqNlI{Ozl\|NEK=
H1975	MnfhT4lv[XOnIFHzd4F6	MUCwMlUh\|ryP	NEDTfFEzPCCq	NX[0VXBXTE2VTx?=	NXLLR3h5\G:nczDuc5QhcW6qaXLpeEBGT0[UIFy4OVhTN1R5OUDNJI12fGGwdD3t[YRq[XSnZDDBb5QheGixc4Doc5J6dGG2aX;u	NX7abmRbOjJ\|M{mzOFI>
MIAPaCa2	M4fFVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIfCN5AzNjVizszN	NEfocHE4OiCq	MlnrSG1UVw>?	MVLoZZMhdm9iZ4Lve5RpKGmwaHnibZRqd25?	MkHlNlA1PjZ3NUW=
MIAPaCa2	MYLDfZRwfG:6aXOgRZN{[Xl?	NX62Rmd7OSEQvF2=	MkDyNVAh\A>?	M{fMU2ROW09?	NH;rOm1p[XNibn:gZ5l1d3SxeHnjbZR6KGG\|c3Xzd4VlKGG\|IIP1dJBz\XO\|aX;uJI9nKGOxbH;ufUBnd3KvYYTpc44>	NUDyZ\|ByOjB2Nk[1OVU>
MIAPaCa2	NEnwUFVCeG:ydH;zbZMhSXO\|YYm=	NH\0RnQyOCEQvF2=	NXPDTVlKOjSqIH;yJFQ5KGh?	NFfM[4pFVVOR	MnO2[I9meyCwb4SgbY5lfWOnIHHwc5B1d3Orcx?=	NXXWcVdVOjB2Nk[1OVU>
MIAPaCa2	NG\IR5dCeG:ydH;zbZMhSXO\|YYm=	M{\uOFIxKM7:TR?=	NFzIdHQzPCCq	NH7oSlhFVVOR	NV3WdVVr\G:nczDuc5QhcW6mdXPlJIFxd3C2b4Ppd{Bie3Onc4Pl[EBieyClYYPwZZNmKDNiYXP0bZZifGmxbh?=	MnfFNlA1PjZ3NUW=
EoL-1	M1S5[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3PjW2lEPTB;NT6xO{BvVQ>?	MYrTRW5ITVJ?
NCI-H720	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWPmOlRsUUN3ME2yOk46OiCwTR?=	NHjMN3BUSU6JRWK=
NCI-SNU-5	M4Hi[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYXMWotUUUN3ME2yPE4yQSCwTR?=	Ml\IV2FPT0WU
EW-3	NGfPR5JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NV71NYw4UUN3ME20Ok4xPCCwTR?=	M4PZc3NCVkeHUh?=
HCC2218	MmDNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGrYTXdKSzVyPUWwMlU6KG6P	MormV2FPT0WU
HuO-3N1	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{PS[mlEPTB;NU[uNFkhdk1?	NELGO5lUSU6JRWK=
DB	NIPtXolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mnn0TWM2OD14MD65OkBvVQ>?	NUHsdI9PW0GQR1XS
HSC-4	NITRbGZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MV3JR\|UxRTZzLkWzJI5O	NHXlSpVUSU6JRWK=
DOK	M{HRR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2rwRWlEPTB;OUOuOlIhdk1?	M3HZ[3NCVkeHUh?=
H9	Mn7uS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWDJR\|UxRTF\|Nz6yJI5O	MlLvV2FPT0WU
NCI-H292	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3LxWWlEPTB;MU[yMlY3KG6P	MkTMV2FPT0WU
HSC-2	NVfCRVlbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2m0c2lEPTB;MU[1MlU4KG6P	NVvFRmVUW0GQR1XS
LU-65	M4XDXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NInre2ZKSzVyPUG2Ok43OSCwTR?=	MnKzV2FPT0WU
BV-173	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVLne3RUUUN3ME2xPFYvPTVibl2=	MULTRW5ITVJ?
LB2241-RCC	M2PoTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4nqd2lEPTB;MUm0Mlk{KG6P	NYK2OlFVW0GQR1XS
KG-1	NIfRfVZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnexTWM2OD1{MESuN\|Qhdk1?	NVPp[I1ZW0GQR1XS
CHL-1	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mn\XTWM2OD1{MEiuOVEhdk1?	MUXTRW5ITVJ?
KYSE-140	NVL5NldCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYPUVZJHUUN3ME2yNFkvQTZibl2=	MUjTRW5ITVJ?
DU-145	M2[1[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MV\JR\|UxRTJzOT6wOEBvVQ>?	NEfLT3NUSU6JRWK=
EW-13	NXz2OYl1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnzaTWM2OD1{MkWuNUBvVQ>?	MYnTRW5ITVJ?
KYSE-450	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NV;qO\|IxUUN3ME2yOFcvQTJibl2=	NUi4Xo1[W0GQR1XS
CAL-72	MnHzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHjiTmJKSzVyPUK2PE44OyCwTR?=	MnP3V2FPT0WU
MEG-01	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYnJR\|UxRTJ5Nj63OkBvVQ>?	NGT6cYFUSU6JRWK=
HCE-T	MmH4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mlz6TWM2OD1{N{muO\|khdk1?	MXjTRW5ITVJ?
NCI-SNU-1	Ml3YS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFfYUY1KSzVyPUK4N{4{OiCwTR?=	M1e0XnNCVkeHUh?=
CAL-27	M2XnTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NUex[2NnUUN3ME2yPFkvODhibl2=	NYLYO5duW0GQR1XS
BALL-1	NUfnblJWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mn;mTWM2OD1{OUeuOFIhdk1?	NHXmNFlUSU6JRWK=
SBC-1	M3uydWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFfET41KSzVyPUOwO{44QSCwTR?=	NIftTItUSU6JRWK=
CAL-54	M1:3Tmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mm\ZTWM2OD1\|MUGuNlMhdk1?	MXLTRW5ITVJ?
TI-73	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYrVUHBIUUN3ME2zNVIvPzVibl2=	Mn7RV2FPT0WU
P12-ICHIKAWA	NV;hR4dET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlHCTWM2OD1\|MkiuNFYhdk1?	NX3oNXVqW0GQR1XS
ACHN	NHjqUIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NIHhXFhKSzVyPUOzNU41KG6P	M2[wfXNCVkeHUh?=
PC-14	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mnq5TWM2OD1\|M{OuOFEhdk1?	MUfTRW5ITVJ?
HCC1806	M2KwT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXvJR\|UxRTN\|Nz61NUBvVQ>?	M2XXUnNCVkeHUh?=
SK-MEL-24	NHPNXZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NV7YZVloUUN3ME2zN\|cvQDdibl2=	NVuxRYZuW0GQR1XS
A4-Fuk	M2XnWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHrKfYJKSzVyPUO1NE4xOiCwTR?=	M2LFRXNCVkeHUh?=
ECC10	NWjEfJBCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVnJR\|UxRTN3Mj65OkBvVQ>?	MoLiV2FPT0WU
KASUMI-1	Moj3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVzkclVlUUN3ME2zOlYvPzNibl2=	M2e1dnNCVkeHUh?=
CAL-33	NI\ERYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MV3JR\|UxRTN5MD65JI5O	MmOwV2FPT0WU
MDA-MB-175-VII	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWfJR\|UxRTN5OD64PEBvVQ>?	NGH3[WxUSU6JRWK=
NUGC-3	Ml:0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1TRemlEPTB;NECxMlgyKG6P	MmHLV2FPT0WU
KY821	M3ezfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVXJR\|UxRTRyOD61O{BvVQ>?	Mn3yV2FPT0WU
CTB-1	MmrJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2XnTGlEPTB;NEK0MlQhdk1?	MmroV2FPT0WU
DoTc2-4510	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1vqb2lEPTB;NESyMlEzKG6P	M4nV[HNCVkeHUh?=
EFO-27	M{XSeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M33SNGlEPTB;NEW0Mlc1KG6P	M3TmT3NCVkeHUh?=
BPH-1	NHriTopIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mli2TWM2OD12OUGuNVYhdk1?	NI\SfnFUSU6JRWK=
KYSE-270	MlPMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGXofWJKSzVyPUS5PE43PSCwTR?=	MYjTRW5ITVJ?
HO-1-N-1	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NEHxeHBKSzVyPUWwPU4zPSCwTR?=	NGHucnFUSU6JRWK=
SK-MEL-1	MnTUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NF7adHRKSzVyPUWxNE46QSCwTR?=	MkT5V2FPT0WU
MOLT-13	NIPmVXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWnuU\|NLUUN3ME21NVQvQDJibl2=	MVfTRW5ITVJ?
TK10	MkXSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFWyOlBKSzVyPUWxOU4yOSCwTR?=	MkjBV2FPT0WU
HN	NH3COFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MUTJR\|UxRTVzNz6zPEBvVQ>?	M{Hxe3NCVkeHUh?=
SCC-15	NYT4RWIxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFvBR4xKSzVyPUWyOU43QCCwTR?=	M4HNdnNCVkeHUh?=
NCI-H358	NU\GOHZjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWXJR\|UxRTV{Nz62OkBvVQ>?	NWTSdWZ7W0GQR1XS
KYSE-180	M{LGZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3fyVmlEPTB;NUOwMlYzKG6P	M4TkbXNCVkeHUh?=
NCI-H82	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWPJR\|UxRTV2MD61JI5O	MnS4V2FPT0WU
NB7	NHW5cW5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWXJR\|UxRTV2Nj6zNkBvVQ>?	M1uxcnNCVkeHUh?=
DSH1	NXPQdlJtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2TrSWlEPTB;NU[2Mlg5KG6P	Mm\MV2FPT0WU
RS4-11	NXnWZVViT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M33OUWlEPTB;NU[4MlU6KG6P	NXXWTot3W0GQR1XS
CAN	MnzSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYr4PFJMUUN3ME21PFAvPzZibl2=	NVTSVYRFW0GQR1XS
Ca9-22	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVnJR\|UxRTV6OD62OEBvVQ>?	NEPjNGpUSU6JRWK=
CAL-39	MmfxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnjCTWM2OD13OU[uN{BvVQ>?	NWPt[YNNW0GQR1XS
NCI-H1623	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFvhZ3hKSzVyPUW5PU4{PiCwTR?=	NWLX[pEzW0GQR1XS
FADU	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MUHJR\|UxRTZyND62PUBvVQ>?	NV\wU495W0GQR1XS
NB69	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NULlfYlKUUN3ME22NVQvOzVibl2=	M37HU3NCVkeHUh?=
Ramos-2G6-4C10	NIDJR\|ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NH61XIlKSzVyPU[yNU41PiCwTR?=	NYq5T4RQW0GQR1XS
LB1047-RCC	NUnUPI1ET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4DkTmlEPTB;NkK1MlI6KG6P	M3zuN3NCVkeHUh?=
MV-4-11	MmHjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1HaWGlEPTB;NkK3Mlchdk1?	MYTTRW5ITVJ?
DBTRG-05MG	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYXjW3VtUUN3ME22N\|IvOjhibl2=	MnLEV2FPT0WU
ME-180	NEjkRWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Ml;hTWM2OD14M{KuPUBvVQ>?	NYjXcG04W0GQR1XS
NBsusSR	M3PTWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NX7reWNJUUN3ME22OFYvPTJibl2=	NFrmWVBUSU6JRWK=
COR-L105	NW\JOm1[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MkDVTWM2OD14NkKuOVMhdk1?	MkjOV2FPT0WU
ETK-1	M{XITmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYjuOHdXUUN3ME22OlIvPTlibl2=	MnPyV2FPT0WU
L-363	NVzifm1TT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmXwTWM2OD14N{GuPVQhdk1?	NEHQNIJUSU6JRWK=
LU-134-A	NW\uSZBRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYDJR\|UxRTdzOT6wPUBvVQ>?	M176d3NCVkeHUh?=
NCI-H1770	NYTpS2UxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NIn2cnlKSzVyPUeyNk41KG6P	NV[xXFNGW0GQR1XS
HAL-01	NHLnb4pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWHJR\|UxRTd\|ND63NUBvVQ>?	M3;pTnNCVkeHUh?=
COLO-684	M3vaS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXXJR\|UxRTd3Mz6wNUBvVQ>?	NGfNdZlUSU6JRWK=
TE-6	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGXqeo1KSzVyPUe2OE4{OSCwTR?=	M4\BTHNCVkeHUh?=
A431	NHPU[\|NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MljZTWM2OD15OECuNFQhdk1?	NYTjUI17W0GQR1XS
LU-135	NGPuRpJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NF\iPYdKSzVyPUe4N{4xOyCwTR?=	MVHTRW5ITVJ?
EC-GI-10	M4PXT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4izR2lEPTB;N{i4MlUzKG6P	MVXTRW5ITVJ?
TE-12	M4rMS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXPJR\|UxRTh{MT6xNUBvVQ>?	MXvTRW5ITVJ?
LoVo	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlmyTWM2OD16NUmuNFYhdk1?	MYDTRW5ITVJ?
23132-87	NYOyZmpzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWrJR\|UxRTh4ND6yPEBvVQ>?	MoDUV2FPT0WU
AU565	NHXmZ5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYLJR\|UxRTh4OT62JI5O	MXnTRW5ITVJ?
DEL	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGG0ZlBKSzVyPUi3O{43PSCwTR?=	MVzTRW5ITVJ?
COR-L88	Mmf1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MlXkTWM2OD16OEKuNlYhdk1?	NH3jd21USU6JRWK=
NCI-H2126	MknpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWjweVZ{UUN3ME24PFIvQDNibl2=	MnPFV2FPT0WU
CAPAN-1	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{G1UmlEPTB;OEizMlI6KG6P	NE\0OmFUSU6JRWK=
BT-474	M1jSUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnHnTWM2OD17M{iuNVQhdk1?	NVv1coFzW0GQR1XS
BHY	MoPjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWfKfGJZUUN3ME25O\|UvPDhibl2=	M4L0[3NCVkeHUh?=
HT-3	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWTJR\|UxRTl6Mj60NUBvVQ>?	Mon6V2FPT0WU
SK-NEP-1	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MV\JR\|UxRTl6OT60OEBvVQ>?	NEjtbIFUSU6JRWK=
MS-1	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MUfJR\|UxRTl7ND62PUBvVQ>?	NHnLU2ZUSU6JRWK=
DOHH-2	NH7kN4RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGe0fJJKSzVyPUGuNFAxOjFizszN	M1XRRnNCVkeHUh?=
NCI-H1304	NU\oeJdET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnTSTWM2OD1zLkCxOlQ{KM7:TR?=	NVz5e5lKW0GQR1XS
EM-2	NWLweHVET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{\PVmlEPTB;MT6wN\|AyPiEQvF2=	NVHtR4hQW0GQR1XS
MHH-PREB-1	NETIeHhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M333b2lEPTB;MT6wPFQ2OSEQvF2=	MWfTRW5ITVJ?
KU-19-19	NGnNblhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mm\rTWM2OD1zLkC4OVQyKM7:TR?=	NEDEbYdUSU6JRWK=
NCI-H1648	NFHROpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MoXkTWM2OD1zLkGwOlE3KM7:TR?=	MUXTRW5ITVJ?
MKN1	NELYZotIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFW5R\|BKSzVyPUGuNlE6QDdizszN	NIGzdoxUSU6JRWK=
SNU-449	M1;ON2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1nrZmlEPTB;MT6yNlIxQCEQvF2=	M4TsUXNCVkeHUh?=
OAW-42	NVjxWG9kT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1vB[GlEPTB;MT6yO\|gzPSEQvF2=	MUDTRW5ITVJ?
769-P	NIf6NFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4DLR2lEPTB;MT6yO\|kyQCEQvF2=	M2D3SnNCVkeHUh?=
SW1088	Mm\jS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3f2dGlEPTB;MT6yPVYxPyEQvF2=	NVnjSZNbW0GQR1XS
GCIY	NFP3WINIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVTJR\|UxRTFwM{CxN\|Ih\|ryP	M{niT3NCVkeHUh?=
CTV-1	NE\wU3ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1\JWWlEPTB;MT6zNFgh\|ryP	MXLTRW5ITVJ?
NCI-H1092	NXHqZXJYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NEj0XIVKSzVyPUGuN\|A5PSEQvF2=	NGnOclNUSU6JRWK=
NKM-1	NFXZTWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MUnJR\|UxRTFwM{K1PVch\|ryP	NHm1[HlUSU6JRWK=
NCI-H1650	NX6wVJpoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFHJNY1KSzVyPUGuN\|M1QDJizszN	NVHsNoxQW0GQR1XS
SW954	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MoToTWM2OD1zLkO0NFQ5KM7:TR?=	MUjTRW5ITVJ?
SW48	NFS4bWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWHzdI5GUUN3ME2xMlM3PjF6IN88US=>	NEHaSWxUSU6JRWK=
SK-N-DZ	M2m1VWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1e2V2lEPTB;MT6zOlk1PyEQvF2=	M4TBdnNCVkeHUh?=
KMOE-2	M1LiNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2TMdWlEPTB;MT6zPVgyPSEQvF2=	M4XSb3NCVkeHUh?=
NB5	NIrrOopIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFjscGFKSzVyPUGuOFA5QTRizszN	M{HNS3NCVkeHUh?=
CCRF-CEM	M2ToRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYDiSo5FUUN3ME2xMlQyOTFizszN	M3Prb3NCVkeHUh?=
RH-1	M3i4TGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NIXte3FKSzVyPUGuOFEyOzZizszN	NWrYOJh6W0GQR1XS
NCI-H526	MkKwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGHoUI9KSzVyPUGuOFM5OjZizszN	NUm3ZYNyW0GQR1XS
697	MoLUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MlPvTWM2OD1zLkS0NVA1KM7:TR?=	NXjiSIw3W0GQR1XS
J82	MkjIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{jPXmlEPTB;MT60OVc3PiEQvF2=	NXLKUZlEW0GQR1XS
BE-13	MnzWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MoHCTWM2OD1zLkWwOlcyKM7:TR?=	Mm\uV2FPT0WU
SAS	NWnLTppIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXHJR\|UxRTFwNUG2NlIh\|ryP	MkjyV2FPT0WU
SCC-25	MoHDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHzMPHVKSzVyPUGuOVI{OjJizszN	NHPZVVlUSU6JRWK=
LAMA-84	NXnK[2R4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1y3XWlEPTB;MT61N\|gyPSEQvF2=	MV\TRW5ITVJ?
HSC-3	M4DyVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NIqwfoRKSzVyPUGuOVQ{QCEQvF2=	M4PpVnNCVkeHUh?=
BT-549	MlvmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mkn4TWM2OD1zLkW4O\|Q4KM7:TR?=	NX;pNHJjW0GQR1XS
ML-2	M3HUdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3HR[WlEPTB;MT62OFAzQSEQvF2=	NV7UN2xHW0GQR1XS
BB30-HNC	M1zCUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MmnpTWM2OD1zLk[4PVczKM7:TR?=	M4nwSXNCVkeHUh?=
PANC-03-27	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NUHYSpJXUUN3ME2xMlcxOTN7IN88US=>	MmHTV2FPT0WU
COLO-678	M3;0Nmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NX7NfFN5UUN3ME2xMlc{PDR2IN88US=>	M1z0eXNCVkeHUh?=
NCI-H1666	M3;ifGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NUfEXJNTUUN3ME2xMlc1PzB2IN88US=>	NYnXd2t3W0GQR1XS
NCI-H209	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXHOXVhHUUN3ME2xMlc4OjZ7IN88US=>	MYfTRW5ITVJ?
EPLC-272H	NEHF[XFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M124XmlEPTB;MT64OVU1QSEQvF2=	NFnsPI5USU6JRWK=
OMC-1	MmPGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NIHPVndKSzVyPUGuPVk5QDhizszN	M4rvVHNCVkeHUh?=
HCC70	M2Lmbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NW\YWYlMUUN3ME2yMlAxQDF3IN88US=>	Moq1V2FPT0WU
CAL-12T	NUjVSZBGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWHtNpNkUUN3ME2yMlAyQDZzIN88US=>	NWHNR3lMW0GQR1XS
TGBC24TKB	M1TrNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYDJR\|UxRTJwMEK5OlEh\|ryP	MWrTRW5ITVJ?
EKVX	NH\NTIxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NG[4SXBKSzVyPUKuNFQ6OzlizszN	NEDBbZNUSU6JRWK=
SW1116	MlT3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MmPmTWM2OD1{LkC2NFA6KM7:TR?=	M2K5VXNCVkeHUh?=
NCI-H2009	NH3FZm5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGHjS5RKSzVyPUKuNFYzOTRizszN	NU\3[o1HW0GQR1XS
RPMI-8866	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1PsTGlEPTB;Mj6wPFQ5OSEQvF2=	NGHncndUSU6JRWK=
KARPAS-45	NXrTWWQ2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVvJR\|UxRTJwMUK0O\|kh\|ryP	MX3TRW5ITVJ?
RXF393	NFjG[25Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3nkWmlEPTB;Mj6xN\|A{PiEQvF2=	M1PrN3NCVkeHUh?=
786-0	NF\DOVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NX;ubXBsUUN3ME2yMlE5PDB4IN88US=>	M1vSUnNCVkeHUh?=
SCC-4	MlXFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXLJR\|UxRTJwMkG3O\|Yh\|ryP	MlHHV2FPT0WU
BT-20	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MoTFTWM2OD1{LkK2O\|Q1KM7:TR?=	MUHTRW5ITVJ?
A498	MkDGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NV7JcIczUUN3ME2yMlI6PDF3IN88US=>	Mn;RV2FPT0WU
IGROV-1	NGTuUodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2fjPGlEPTB;Mj6zNVI{PyEQvF2=	M{PGcHNCVkeHUh?=
JVM-3	NXnLT\|k1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWW3VWVFUUN3ME2yMlM1PjR\|IN88US=>	MWLTRW5ITVJ?
NCI-H2170	NYXKZYNIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVHJR\|UxRTJwM{S3PFMh\|ryP	MkPPV2FPT0WU
EW-18	MmPQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M17rdWlEPTB;Mj6zOVQ4OSEQvF2=	M4[xPHNCVkeHUh?=
KU812	NHnS[2xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWLJR\|UxRTJwM{[3O\|kh\|ryP	MnjwV2FPT0WU
NY	NF;0SVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnnNTWM2OD1{LkO3Nlch\|ryP	M1j6[3NCVkeHUh?=
HTC-C3	NIDGU2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHjhOnhKSzVyPUKuOFIzPjdizszN	NFvTNFJUSU6JRWK=
CFPAC-1	M33Bcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{izV2lEPTB;Mj60N\|g3PCEQvF2=	M3HMS3NCVkeHUh?=
HH	NXG5bHp6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4XuZmlEPTB;Mj60PVg2PCEQvF2=	Mo\KV2FPT0WU
MKN7	NX;JR5B3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Ml64TWM2OD1{Lk[yO\|Q5KM7:TR?=	Mn;1V2FPT0WU
TE-8	NUjzVGRoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2TtRWlEPTB;Mj62N\|Y2OyEQvF2=	MoP1V2FPT0WU
MC-IXC	MmTsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3fjcWlEPTB;Mj62OFQ2OyEQvF2=	NGfHbIlUSU6JRWK=
DMS-79	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlnBTWM2OD1{Lk[5Nlg1KM7:TR?=	NEfBfZRUSU6JRWK=
Detroit562	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{LycWlEPTB;Mj62PVg1PSEQvF2=	NFTYNYhUSU6JRWK=
HuP-T4	M1vpc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVXJR\|UxRTJwN{K4NVgh\|ryP	Mk\nV2FPT0WU
QIMR-WIL	NHK1OWRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnrmTWM2OD1{Lke1PVUzKM7:TR?=	MlfoV2FPT0WU
BB65-RCC	NYXPO29oT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NIrmWo5KSzVyPUKuPFA4OTNizszN	MVvTRW5ITVJ?
PC-3	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mli2TWM2OD1{LkizN\|E4KM7:TR?=	NIf1[o1USU6JRWK=
OVCAR-3	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mm\CTWM2OD1{Lki1OVk1KM7:TR?=	M4TIW3NCVkeHUh?=
KYSE-510	NGXFUmpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MoPHTWM2OD1{Lki2O\|g3KM7:TR?=	NXvsXotNW0GQR1XS
HC-1	NGLGSoxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHuxNFVKSzVyPUKuPVQxOTJizszN	M{fwWnNCVkeHUh?=
NCI-H1693	Mo\jS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NIn2S3pKSzVyPUKuPVU5QTdizszN	NVnEbXlbW0GQR1XS
DU-4475	NH3PR\|RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnS1TWM2OD1{Lkm5NFUzKM7:TR?=	NWjo[nQ5W0GQR1XS
COLO-680N	MlqyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWfUVlFGUUN3ME2zMlAxPDl3IN88US=>	MX3TRW5ITVJ?
MN-60	NWrqNpZsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYfJR\|UxRTNwMES5O\|Qh\|ryP	M4fqXnNCVkeHUh?=
BCPAP	M3PtNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NEnnb3dKSzVyPUOuNFgzQTVizszN	M3PYRXNCVkeHUh?=
647-V	Mn2zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWO0doQ2UUN3ME2zMlE3OjJizszN	M3\ZWHNCVkeHUh?=
HT-1376	NVy5Nnc{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NF21Z5hKSzVyPUOuNlA2ODZizszN	MUDTRW5ITVJ?
NCI-H1793	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHjxfVRKSzVyPUOuNlExQThizszN	M{DMUHNCVkeHUh?=
SW1463	NWTqfXFsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{TWW2lEPTB;Mz6yOlE6OiEQvF2=	NYHpUXU1W0GQR1XS
NCI-H727	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MUnJR\|UxRTNwM{i1PFQh\|ryP	Mo\UV2FPT0WU
LB771-HNC	NV3jXIlDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWHJR\|UxRTNwM{mxNlYh\|ryP	Mme5V2FPT0WU
D-542MG	NWH1U2x5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NUTR[oJFUUN3ME2zMlQ1OjJ{IN88US=>	M2PLNnNCVkeHUh?=
NTERA-S-cl-D1	MorHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVjJR\|UxRTNwNES5OVch\|ryP	M{LyVnNCVkeHUh?=
C8166	M3XR[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4j3U2lEPTB;Mz60OlUzOSEQvF2=	M3HCNXNCVkeHUh?=
639-V	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnO5TWM2OD1\|LkW3O\|kzKM7:TR?=	MmDMV2FPT0WU
TE-1	NXS3TFlvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{fY[2lEPTB;Mz61PVE3QSEQvF2=	MUXTRW5ITVJ?
OAW-28	NFXKTo5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MoLSTWM2OD1\|LkW5OFI3KM7:TR?=	M4m1[XNCVkeHUh?=
SK-LU-1	M3e5TGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHrPSmdKSzVyPUOuOlA3PDVizszN	M1vpV3NCVkeHUh?=
CaR-1	NGTh[GNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MojZTWM2OD1\|Lk[xNFQ5KM7:TR?=	M4DNOnNCVkeHUh?=
A2780	MojxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFTQc4JKSzVyPUOuOlQxQDlizszN	NH;FTHlUSU6JRWK=
C2BBe1	NIrjZ\|dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MkDmTWM2OD1\|Lk[0OFA4KM7:TR?=	M33jdXNCVkeHUh?=
SK-MES-1	NH7YeGxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYrnSVExUUN3ME2zMlY1PjF2IN88US=>	MojmV2FPT0WU
PANC-10-05	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWrZdXR2UUN3ME2zMlczODd{IN88US=>	M1\SbnNCVkeHUh?=
J-RT3-T3-5	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXTJR\|UxRTNwN{W0NFYh\|ryP	MoC5V2FPT0WU
ES4	M1ziZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnGxTWM2OD1\|LkiyNlg3KM7:TR?=	NGPXOFdUSU6JRWK=
NCI-H28	MnfnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3\GeWlEPTB;Mz64Nlk3OSEQvF2=	NFT4UXpUSU6JRWK=
NCI-H1155	MmHVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYPJR\|UxRTNwOESxOVkh\|ryP	NF;uN5hUSU6JRWK=
KURAMOCHI	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mkf1TWM2OD1\|Lki2NFU3KM7:TR?=	MXHTRW5ITVJ?
NCI-H69	NUWxNY5WT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MkjRTWM2OD1\|LkmwNVc5KM7:TR?=	MWTTRW5ITVJ?
IST-MES1	MkXyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NU\FdYdSUUN3ME2zMlk1ODJ7IN88US=>	M3qycXNCVkeHUh?=
NH-12	MlXHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYfENnpbUUN3ME2zMlk1OTh5IN88US=>	NXvWemZNW0GQR1XS
JVM-2	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGXSPHdKSzVyPUOuPVQ4PTJizszN	MlXtV2FPT0WU
EW-16	NVPOWXljT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NEHreYhKSzVyPUOuPVU2PzdizszN	MmqyV2FPT0WU
NCI-H441	MonkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4LjSmlEPTB;Mz65O\|AyPCEQvF2=	M1z3NHNCVkeHUh?=
RCC10RGB	MlGyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWLJR\|UxRTRwMEGyOFYh\|ryP	M1XGWnNCVkeHUh?=
TCCSUP	M1fx[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHzwcm9KSzVyPUSuNVExPSEQvF2=	NUHxNWJrW0GQR1XS
HL-60	NY\xUlhKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mof3TWM2OD12LkGyNlQyKM7:TR?=	MnPmV2FPT0WU
EW-11	NXzhV2wzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2nBc2lEPTB;ND6xN\|I3OSEQvF2=	MX7TRW5ITVJ?
KARPAS-299	NYrxN5NYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4jHOWlEPTB;ND6zNVAyOyEQvF2=	NX36d4JtW0GQR1XS
SNU-C2B	NIDvZ3ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVfJR\|UxRTRwM{S2PFYh\|ryP	M4DHR3NCVkeHUh?=
LU-139	NXL3ZVZuT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mne4TWM2OD12LkO3NlQ4KM7:TR?=	MlrkV2FPT0WU
HCC1937	M2LMSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MkfWTWM2OD12LkO3PVk{KM7:TR?=	MUfTRW5ITVJ?
GR-ST	M17Md2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NF\Ob5NKSzVyPUSuOFMyQCEQvF2=	NFqyR4VUSU6JRWK=
SK-OV-3	M2LId2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGizSXNKSzVyPUSuOFYxPDJizszN	MYrTRW5ITVJ?
A172	NVfHflRET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NIq4TXFKSzVyPUSuOVU2OjFizszN	NHTnUm9USU6JRWK=
NB10	M3:wOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{njfmlEPTB;ND61PVc5OSEQvF2=	Mo\aV2FPT0WU
P30-OHK	M1TKOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3zEfGlEPTB;ND64NVkzQSEQvF2=	MYPTRW5ITVJ?
KYSE-520	M2HqN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mk\GTWM2OD12Lki4NFE5KM7:TR?=	NV23XFl3W0GQR1XS
KNS-62	NH3vUolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MkPUTWM2OD12LkmwPFA4KM7:TR?=	MofZV2FPT0WU
ES1	NWS5d4w2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGDPc4RKSzVyPUSuPVYxOzVizszN	NXjLUG45W0GQR1XS
KOSC-2	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXTJR\|UxRTRwOUm5OVkh\|ryP	NVPUTW5xW0GQR1XS
TE-9	NFLvTnZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NUXHcYN5UUN3ME21MlAyPTJ3IN88US=>	MX\TRW5ITVJ?
NCI-H1838	M161[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NF\HOmZKSzVyPUWuNFIxPzZizszN	MnHnV2FPT0WU
KP-N-YN	NUXONIVzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4jveGlEPTB;NT6xNlU6OSEQvF2=	MkfaV2FPT0WU
ALL-PO	NGT5VpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3r2VmlEPTB;NT6yNlU5PyEQvF2=	NXfWN3l4W0GQR1XS
NOMO-1	MnfkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NULaeYw4UUN3ME21MlI{OTd4IN88US=>	MUjTRW5ITVJ?
CGTH-W-1	NXfGb3U1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFjDZ21KSzVyPUWuN\|g2QDRizszN	M2fWTHNCVkeHUh?=
ATN-1	NFrOWWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NETKbHdKSzVyPUWuOFEyQDRizszN	M1v4WnNCVkeHUh?=
AGS	M2rURWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NF;MNm1KSzVyPUWuOFk3OThizszN	NHXFSIlUSU6JRWK=
SW13	NI\LTnNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXjJR\|UxRTVwNUOyOlUh\|ryP	NFH4dFhUSU6JRWK=
SW1990	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NF7QXmNKSzVyPUWuOlIzQDVizszN	MX7TRW5ITVJ?
BFTC-905	NUjyVIZbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXrvOHlwUUN3ME21MlY2QDd6IN88US=>	NEixWmFUSU6JRWK=
RMG-I	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnvUTWM2OD13Lk[1PVQzKM7:TR?=	NYrQenRiW0GQR1XS
HD-MY-Z	M3jxc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHWzNIJKSzVyPUWuOlg2QDFizszN	NXSzSFFZW0GQR1XS
HCC1187	M4jJS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVrsR5I4UUN3ME21MlcyODN{IN88US=>	MUXTRW5ITVJ?
HCC2998	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmiwTWM2OD13LkexPFc4KM7:TR?=	Mn;BV2FPT0WU
RT-112	NUPSTVdET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{PTRWlEPTB;NT65NFI1PSEQvF2=	M1vjd3NCVkeHUh?=
CAKI-1	NF;We2JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVHkTFc3UUN3ME22MlAxQTh3IN88US=>	MYfTRW5ITVJ?
HDLM-2	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mnv1TWM2OD14LkCxOFg6KM7:TR?=	MkCzV2FPT0WU
TE-10	NX75dldIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M17ERWlEPTB;Nj6wOFg{OyEQvF2=	NWLPWGRrW0GQR1XS
KE-37	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWLKWolOUUN3ME22MlA4OjV6IN88US=>	NYq1fYVMW0GQR1XS
RCM-1	MmDRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGDYc5RKSzVyPU[uNFc4OTlizszN	MVTTRW5ITVJ?
Mewo	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mn\mTWM2OD14LkGxOFg4KM7:TR?=	MWjTRW5ITVJ?
L-428	NXrnTXVoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXnJR\|UxRTZwMUiwN\|ch\|ryP	M{K4ZXNCVkeHUh?=
8-MG-BA	M2C0Tmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NIDIV5ZKSzVyPU[uNVk{PzlizszN	NHfZcm1USU6JRWK=
SK-MEL-28	NFfl[nRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MkS2TWM2OD14LkKwPVY4KM7:TR?=	NV\MfGtXW0GQR1XS
VA-ES-BJ	M{HXNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NF;6e2NKSzVyPU[uN\|A1PjJizszN	Ml7KV2FPT0WU
CAL-120	Mn7XS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MY\JR\|UxRTZwNEWxOlIh\|ryP	MmjSV2FPT0WU
GAMG	MorJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MlfqTWM2OD14LkWwOlIh\|ryP	NGrFcmxUSU6JRWK=
MSTO-221H	NIXrUXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2n4SGlEPTB;Nj61NVE4KM7:TR?=	NHq1VGtUSU6JRWK=
GCT	NHmzcmxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NETUZlhKSzVyPU[uOVM{QDdizszN	MlfMV2FPT0WU
SH-4	M2CwUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYHJR\|UxRTZwNUi4OFQh\|ryP	MXrTRW5ITVJ?
Calu-3	M3O0dGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NEnxNmRKSzVyPU[uOlU2PjhizszN	M1jqZnNCVkeHUh?=
SK-HEP-1	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWPJR\|UxRTZwN{G3OVMh\|ryP	M37aT3NCVkeHUh?=
PFSK-1	MmnwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHvWe3hKSzVyPU[uO\|M1PzhizszN	MYfTRW5ITVJ?
NB12	M4D2TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnXFTWM2OD14Lke4OFA1KM7:TR?=	MUnTRW5ITVJ?
A388	NH7RcodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWPKU29DUUN3ME22Mlg6PTJizszN	MkHNV2FPT0WU
KLE	M1y3fmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFrMT5ZKSzVyPU[uPVY2OTZizszN	NUCyW2FXW0GQR1XS
TE-11	M3e0Xmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MUjJR\|UxRTdwMES5Olch\|ryP	NULyTIJTW0GQR1XS
NCI-H2405	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Ml;nTWM2OD15LkC4N\|k{KM7:TR?=	M{n5SXNCVkeHUh?=
OVCAR-4	NYnoPGRyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWSxT2hOUUN3ME23MlE2OzVizszN	NXXqXJF1W0GQR1XS
KP-N-YS	NGPFXlRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{XQZ2lEPTB;Nz6xPFE1KM7:TR?=	NWTUSYVVW0GQR1XS
NOS-1	NF\pdVZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mlf4TWM2OD15LkK1PFI5KM7:TR?=	Mk\TV2FPT0WU
DMS-114	M1HOVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWjPTJJ4UUN3ME23MlI6PjNzIN88US=>	MmnaV2FPT0WU
NCI-H2030	MkTHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4HFcmlEPTB;Nz6zN\|Y6QCEQvF2=	MVfTRW5ITVJ?
HEL	MoPiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Ml3KTWM2OD15LkO3OVIyKM7:TR?=	MoruV2FPT0WU
CAL-62	NYXhWWp7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NV\HVWl5UUN3ME23MlM6QDZ4IN88US=>	NHTJ[2ZUSU6JRWK=
COLO-668	Mln1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{e2XGlEPTB;Nz60N\|k3PyEQvF2=	NUPCcGJ4W0GQR1XS
SKG-IIIa	Mk\1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MY\JR\|UxRTdwNEWzPFEh\|ryP	MXvTRW5ITVJ?
HCC1419	NF7sSJZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MV7JR\|UxRTdwNE[4N\|Mh\|ryP	NF\ybXhUSU6JRWK=
OS-RC-2	M3LEcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NEHke4xKSzVyPUeuOFk5QTRizszN	MWTTRW5ITVJ?
COLO-829	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NIjRcnRKSzVyPUeuOlY1PjNizszN	NXPPZoprW0GQR1XS
NB13	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXXJR\|UxRTdwOEK2Olch\|ryP	M{PJdXNCVkeHUh?=
DK-MG	M1ntNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWnSXXl3UUN3ME23Mlg{OjBzIN88US=>	NWXKfXlRW0GQR1XS
SHP-77	NVW1THZET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MUTJR\|UxRTdwOE[2OVMh\|ryP	MV;TRW5ITVJ?
NCI-H661	M3vPRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NIPHUZlKSzVyPUiuNFU5PjdizszN	NWe3eHBZW0GQR1XS
AM-38	NFK3dHRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYPJR\|UxRThwMU[yPEDPxE1?	Mn3XV2FPT0WU
VM-CUB-1	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXrJR\|UxRThwMUewNlkh\|ryP	NVzGVFJHW0GQR1XS
KYSE-70	M32wTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MU\JR\|UxRThwMUm3OlEh\|ryP	MVPTRW5ITVJ?
5637	NFLPVVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGTRfVFKSzVyPUiuN\|ExPTVizszN	MV;TRW5ITVJ?
TGBC11TKB	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MV7JR\|UxRThwNE[xOlQh\|ryP	MnL3V2FPT0WU
EGI-1	NUjjPGlMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mmm0TWM2OD16Lk[wNFg5KM7:TR?=	NFfDRnpUSU6JRWK=
D-392MG	M4\vRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWDJR\|UxRThwNk[yNVQh\|ryP	MXXTRW5ITVJ?
A673	NGjqZYVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmnITWM2OD16Lk[3OlEyKM7:TR?=	Mln4V2FPT0WU
COLO-792	NFfPflBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1zK[WlEPTB;OD63OFk1PiEQvF2=	NXPuS3d3W0GQR1XS
NCI-H1792	M13JR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnTTTWM2OD16Lki4PVA{KM7:TR?=	NIH5VWJUSU6JRWK=
LS-1034	NHvTd2FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYP1elE1UUN3ME24Mlk1PjV{IN88US=>	M{LGRnNCVkeHUh?=
D-566MG	M3;tT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1v3UmlEPTB;OT6wNVgyKM7:TR?=	NGLueWpUSU6JRWK=
NCI-H226	NXfPV29tT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NEHYZYdKSzVyPUmuNFkh\|ryP	NHKwSVdUSU6JRWK=
ChaGo-K-1	Mn;BS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MknnTWM2OD17LkGwOVc6KM7:TR?=	NGryO2lUSU6JRWK=
NCI-H2228	NIf1VpBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MV;JR\|UxRTlwMUGwPFEh\|ryP	NFPoW29USU6JRWK=
RPMI-8226	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2\mTGlEPTB;OT6xNVMxPCEQvF2=	MoDNV2FPT0WU
BFTC-909	NVOxXXNLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmrFTWM2OD17LkG4Nlk4KM7:TR?=	NWfERXBkW0GQR1XS
HPAF-II	NFSwW2pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NV3IT3BWUUN3ME25MlIzPTF6IN88US=>	MYnTRW5ITVJ?
Capan-2	NHLLT3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MW\JR\|UxRTlwNECxNFkh\|ryP	M1j1OXNCVkeHUh?=
IA-LM	Moe5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NImybVZKSzVyPUmuOFE6PjZizszN	NXf5T5lGW0GQR1XS
KP-4	MmH3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4nafmlEPTB;OT60PFg{QCEQvF2=	NGXWbGpUSU6JRWK=
A101D	NXfyOVJMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2m3W2lEPTB;OT61NVcyQSEQvF2=	NVPhNGd1W0GQR1XS
EFO-21	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MUHJR\|UxRTlwNUi3N\|Uh\|ryP	MYXTRW5ITVJ?
C32	NELHNXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXTMZodOUUN3ME25MlY{OzRizszN	M4niWXNCVkeHUh?=
SW837	M3L2fGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXzJR\|UxRTlwOES4NkDPxE1?	NF\4TVJUSU6JRWK=
OCI-AML2	NIH1VXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmW0TWM2OD17Lki2PVYh\|ryP	NGrFRo1USU6JRWK=
NCI-H1355	M1LiNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXnJR\|UxRTlwOUSwPFgh\|ryP	MXjTRW5ITVJ?
NCI-H2342	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYPJR\|UxRTFyLkCxOVUh\|ryP	NVfIeJVoW0GQR1XS
A204	M{nNPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NH7udGlKSzVyPUGwMlA1PjZizszN	MlT5V2FPT0WU
CAL-51	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MY\JR\|UxRTFyLkC4O\|ch\|ryP	NEDkTVNUSU6JRWK=
HCE-4	NXHiO2FZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXr0S4RqUUN3ME2xNE4yOTJ{IN88US=>	NIf6boxUSU6JRWK=
NCI-H810	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXXJR\|UxRTFyLkG1PVch\|ryP	Mny5V2FPT0WU
DJM-1	MmX5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NEi5TVlKSzVyPUGwMlE4OzJizszN	NELaNodUSU6JRWK=
SK-UT-1	M4nldGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NIDhd4tKSzVyPUGwMlI2PzRizszN	NFrxVnpUSU6JRWK=
U031	NI\aWmhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MULJR\|UxRTFyLkK2PFYh\|ryP	NIHRVldUSU6JRWK=
YH-13	MoXoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWPoWJJuUUN3ME2xNE4{ODV5IN88US=>	MUDTRW5ITVJ?
K5	NULwWZlYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MUnJR\|UxRTFyLkOzPVUh\|ryP	NGXXTGRUSU6JRWK=
HEC-1	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M17QfWlEPTB;MUCuOFA5OSEQvF2=	M{jD[3NCVkeHUh?=
A2058	MoH4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MkLMTWM2OD1zMD61OFkyKM7:TR?=	NXHYWlZ6W0GQR1XS
SW962	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NEHrXYVKSzVyPUGwMlYzODRizszN	M1z0bHNCVkeHUh?=
VMRC-RCZ	NFnqcIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NE\aRZlKSzVyPUGwMlY4PDlizszN	NFLVO2JUSU6JRWK=
D-336MG	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWnJR\|UxRTFyLkewNFUh\|ryP	NWXuW2JzW0GQR1XS
LXF-289	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NIfoXGdKSzVyPUGwMlc6PjdizszN	M1XSWXNCVkeHUh?=
SW900	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MkfJTWM2OD1zMD64NlI5KM7:TR?=	MYPTRW5ITVJ?
K-562	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mlz2TWM2OD1zMD64N\|k2KM7:TR?=	M{HP[nNCVkeHUh?=
HCC38	NVf6dW51T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{fVO2lEPTB;MUCuPVcyPiEQvF2=	MoL6V2FPT0WU
SF-295	NEP2TmhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVnJR\|UxRTFyLkm5NFIh\|ryP	NUHyWW5SW0GQR1XS
LB831-BLC	MmjQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVnJR\|UxRTFzLkK1OVYh\|ryP	NU\l[WRyW0GQR1XS
FTC-133	M2G5UWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MmDNTWM2OD1zMT6zNFgyKM7:TR?=	NGjVTlNUSU6JRWK=
HCC1954	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mlf5TWM2OD1zMT60N\|Yh\|ryP	NIqwUo1USU6JRWK=
GOTO	M4Tufmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NF\PTZdKSzVyPUGxMlUzODZizszN	M1rYPHNCVkeHUh?=
LS-411N	M1TUXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NUXVUHJJUUN3ME2xNU43OTBzIN88US=>	NX\aT2hNW0GQR1XS
RPMI-7951	NH;EW4RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{HISmlEPTB;MUGuOlM1QCEQvF2=	NHvKUo1USU6JRWK=
NCI-H1299	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4LrXGlEPTB;MUGuOlY1PyEQvF2=	M3PnXHNCVkeHUh?=
MLMA	NHG3[XFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MY\JR\|UxRTFzLk[5PVch\|ryP	MlTSV2FPT0WU
MMAC-SF	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{jSbmlEPTB;MUGuO\|I2OiEQvF2=	Ml75V2FPT0WU
UM-UC-3	M1Xt[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MULJR\|UxRTFzLke0NlEh\|ryP	M2TjO3NCVkeHUh?=
SCC-9	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFS2UIlKSzVyPUGxMlgyPTFizszN	NVe1WIRkW0GQR1XS
HOS	NY[2RmJPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MUnJR\|UxRTFzLki2PFMh\|ryP	MlXTV2FPT0WU
OE19	NHPvVohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVrJR\|UxRTFzLkmzOlch\|ryP	Mn3JV2FPT0WU
Mo-T	NXn4TVF[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFvKTYZKSzVyPUGxMlk2PDFizszN	NHf1VnZUSU6JRWK=
CAMA-1	NELs[VNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NUDRbGROUUN3ME2xNk4yPjN\|IN88US=>	MmHrV2FPT0WU
U-118-MG	M17VOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYfm[VVwUUN3ME2xNk4zPDRzIN88US=>	Mo[0V2FPT0WU
KS-1	M{ThU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mn6wTWM2OD1zMj6yPFMzKM7:TR?=	MWnTRW5ITVJ?
JAR	M3OzTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVjJR\|UxRTF{LkOzOlkh\|ryP	M3L1S3NCVkeHUh?=
ABC-1	Mnn6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYfvWG45UUN3ME2xNk4{PDFizszN	MY\TRW5ITVJ?
Daoy	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NV3xc3RjUUN3ME2xNk41PTR{IN88US=>	MWPTRW5ITVJ?
C3A	Mn7PS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGrTboVKSzVyPUGyMlU4QDVizszN	MWHTRW5ITVJ?
GT3TKB	NHu5VVZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MUDJR\|UxRTF{Lk[zNlch\|ryP	NFjBPHBUSU6JRWK=
DMS-273	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4naOmlEPTB;MUKuPFY{OyEQvF2=	NWTjdYN6W0GQR1XS
G-361	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MULJR\|UxRTF{LkmxNlkh\|ryP	M3LhXnNCVkeHUh?=
RH-18	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWjJR\|UxRTF\|LkK5OlIh\|ryP	MlexV2FPT0WU
SN12C	MlPxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGDDSIFKSzVyPUGzMlM5ODhizszN	NGrD[HpUSU6JRWK=
NCI-H1993	M1nJd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2f4VmlEPTB;MUOuOFI5PSEQvF2=	MVXTRW5ITVJ?
LOXIMVI	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MUjJR\|UxRTF\|Lk[xOVEh\|ryP	MmXpV2FPT0WU
SK-PN-DW	NXvUTGsyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVnJR\|UxRTF\|Lki0Nlch\|ryP	M4SzN3NCVkeHUh?=
KALS-1	MljKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2TjNWlEPTB;MUOuPFUzPSEQvF2=	NWrtTJViW0GQR1XS
LAN-6	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFjnSpBKSzVyPUG0MlI2OyEQvF2=	M2XZN3NCVkeHUh?=
A549	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXzJR\|UxRTF2LkS3NVIh\|ryP	M{ftXHNCVkeHUh?=
RD	NILp[FFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWjJR\|UxRTF2LkS4NVMh\|ryP	MYrTRW5ITVJ?
TGBC1TKB	NUe3blJnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NUfTV4d[UUN3ME2xOE43PjF3IN88US=>	NFP4VnlUSU6JRWK=
NCI-H630	NXHH[Hg{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2mxbWlEPTB;MUSuPVQ3PyEQvF2=	MUDTRW5ITVJ?
MIA-PaCa-2	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGfzOoFKSzVyPUG0Mlk3QSEQvF2=	M2PnS3NCVkeHUh?=
NCI-H1755	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NX\FT41PUUN3ME2xOE46QTV\|IN88US=>	NIjTboxUSU6JRWK=
MOLT-4	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NH\uVpdKSzVyPUG1MlA1QTdizszN	MmD1V2FPT0WU
CW-2	NH\n[2ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4nId2lEPTB;MUWuNVQzOSEQvF2=	M3Hz[nNCVkeHUh?=
COLO-320-HSR	NWnDUXhvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXXJR\|UxRTF3LkWzNFch\|ryP	MVTTRW5ITVJ?
UMC-11	NYjRbGpoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGPPPHVKSzVyPUG1Mlc2OjNizszN	MoTiV2FPT0WU
MCF7	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmTFTWM2OD1zNT64NVQ2KM7:TR?=	NXm4UpVLW0GQR1XS
NCI-H23	MofZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MX\JR\|UxRTF3Lki0N\|gh\|ryP	MlXJV2FPT0WU
HuCCT1	NUm3bYpLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mn;FTWM2OD1zNT64O\|Qh\|ryP	MoDrV2FPT0WU
MPP-89	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXfWSWZUUUN3ME2xOU46PDF5IN88US=>	M4PQTnNCVkeHUh?=
HT55	MoLqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1;icGlEPTB;MUWuPVQ4QCEQvF2=	M2PRbHNCVkeHUh?=
no-11	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NV;SOFBtUUN3ME2xOU46PjZ\|IN88US=>	M1\EWnNCVkeHUh?=
GP5d	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3zEdWlEPTB;MU[uNlE5PyEQvF2=	M3vDcXNCVkeHUh?=
BHT-101	M3raOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHW2cJFKSzVyPUG2MlI1OzlizszN	M4fNfnNCVkeHUh?=
M059J	M3iyUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MlvvTWM2OD1zNj6yPFQh\|ryP	MYTTRW5ITVJ?
D-283MED	NVTJN5g4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWXJR\|UxRTF4LkSyNFkh\|ryP	M3TQUHNCVkeHUh?=
BEN	NYfjfJJuT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYnJR\|UxRTF4LkWxOVUh\|ryP	MkfMV2FPT0WU
LB373-MEL-D	NGjZd5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{\mSWlEPTB;MU[uO\|I{OiEQvF2=	NVPhNXdTW0GQR1XS
MEL-HO	NGO4TFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVXJR\|UxRTF4Lki4OVQh\|ryP	NUfWRoRTW0GQR1XS
GI-ME-N	NXL3V\|NUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGXzUG1KSzVyPUG2MlkxOzJizszN	M1rpT3NCVkeHUh?=
RKO	NF;VZpBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NX3kPJUzUUN3ME2xO{4xPzR6IN88US=>	NGPlS\|JUSU6JRWK=
MZ2-MEL	MoLqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MlXTTWM2OD1zNz6xN\|Mh\|ryP	M{jE[nNCVkeHUh?=
NCI-H1573	MoraS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVzJR\|UxRTF5LkK4NlYh\|ryP	MUfTRW5ITVJ?
NCI-H1581	M4D1Xmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M13UcmlEPTB;MUeuOFQyOSEQvF2=	NIPnR5BUSU6JRWK=
NCI-H747	M3vBPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3y5SGlEPTB;MUeuOVI6PyEQvF2=	NEWxS2VUSU6JRWK=
SW1783	Ml;HS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mn3iTWM2OD1zNz62OFE2KM7:TR?=	Mon0V2FPT0WU
Calu-6	NHHyNGVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3m0cWlEPTB;MUeuOlc5OiEQvF2=	NV7GdmFQW0GQR1XS
SF268	NUXCT4tOT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWX5ZmZwUUN3ME2xO{43QTZ7IN88US=>	M2HMOHNCVkeHUh?=
ES8	NGDr[YdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXz6S3h3UUN3ME2xO{45PTl\|IN88US=>	MkPuV2FPT0WU
KM-H2	MoHiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWfJR\|UxRTF5Lkm0NVEh\|ryP	NGHFSoNUSU6JRWK=
D-502MG	NFzDUo5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3\4WWlEPTB;MUeuPVgxQCEQvF2=	M4nx[nNCVkeHUh?=
HLE	M{TUdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHTJRmtKSzVyPUG4MlMyPDhizszN	Mnn6V2FPT0WU
SW982	NVPJOW9DT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWPJR\|UxRTF6LkSwO\|Uh\|ryP	M1LXR3NCVkeHUh?=
MDA-MB-361	NYPlPHlOT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{LI[WlEPTB;MUiuOVU5QCEQvF2=	NFX5SlRUSU6JRWK=
NCI-H1563	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MojpTWM2OD1zOD63NVI1KM7:TR?=	NXjSOZJHW0GQR1XS
MFE-280	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWDJR\|UxRTF6LkeyPVMh\|ryP	MkPHV2FPT0WU
U251	NEP2dpdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXfJR\|UxRTF6LkezOFch\|ryP	NXfteoxFW0GQR1XS
KNS-42	NWS5S4VIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFntPXhKSzVyPUG4MlgxOTVizszN	MVrTRW5ITVJ?
U-266	NWKzXJd[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWHJR\|UxRTF6Lki2OFkh\|ryP	NGXJfndUSU6JRWK=
OVCAR-8	MoO5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXK2[3hTUUN3ME2xPE46Ojd4IN88US=>	MoDzV2FPT0WU
MFH-ino	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmrSTWM2OD1zOD65OlY6KM7:TR?=	NFXq[WhUSU6JRWK=
D-263MG	NH\VUotIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXjzcJpmUUN3ME2xPU4xOTd{IN88US=>	MUfTRW5ITVJ?
NCI-H1437	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHf5UXVKSzVyPUG5MlA1PjdizszN	NIfxR\|dUSU6JRWK=
NCI-H1048	NHTKWGdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2jZe2lEPTB;MUmuNlMzPiEQvF2=	MXXTRW5ITVJ?
NCI-H446	MmfYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NEfpRoFKSzVyPUG5MlM2QDlizszN	MWTTRW5ITVJ?
NCI-N87	NE\6TJZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MkfYTWM2OD1zOT61PVkzKM7:TR?=	NUX3ZndzW0GQR1XS
WM-115	MlHES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVzJR\|UxRTF7Lk[3O\|Qh\|ryP	MkfXV2FPT0WU
HuH-7	M3XU[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MlriTWM2OD1zOT63OFIyKM7:TR?=	MV\TRW5ITVJ?
NCI-H650	NEXGUXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1PkVWlEPTB;MUmuO\|UxQCEQvF2=	MYnTRW5ITVJ?
TYK-nu	MnTsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MUXJR\|UxRTF7LkizO\|gh\|ryP	M33iWXNCVkeHUh?=
Becker	NEPjO41Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4jHcmlEPTB;MUmuPFU1PyEQvF2=	NHXHOm1USU6JRWK=
BB49-HNC	NXHDVFViT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NEPk[ZFKSzVyPUG5MlkzKM7:TR?=	Mle1V2FPT0WU
HGC-27	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXP0UohXUUN3ME2yNE4yOzl2IN88US=>	MXXTRW5ITVJ?
SiHa	NEDQVGFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVHJR\|UxRTJyLkO3NVIh\|ryP	M3L0W3NCVkeHUh?=
LB2518-MEL	NGXRUWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mof1TWM2OD1{MD6zO\|M6KM7:TR?=	NIW2enNUSU6JRWK=
TE-5	NGS5NFZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4nrRmlEPTB;MkCuO\|Q5OiEQvF2=	Mn\SV2FPT0WU
IST-SL1	MorKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MV3JR\|UxRTJyLke4O\|kh\|ryP	M4TPRnNCVkeHUh?=
A375	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M135OGlEPTB;MkGuNFU3PyEQvF2=	MlrGV2FPT0WU
MC116	NYjm[YxDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXLJR\|UxRTJzLkC3NlMh\|ryP	MWjTRW5ITVJ?
GI-1	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnHwTWM2OD1{MT6xO{DPxE1?	MlXXV2FPT0WU
HOP-62	M3\ydmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2jPfGlEPTB;MkGuNlc5PCEQvF2=	NYLESWVjW0GQR1XS
PA-1	NVTv[mVnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2nLdGlEPTB;MkGuNlc5PyEQvF2=	NIW4T4NUSU6JRWK=
HT	NID0bHBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MojUTWM2OD1{MT60N\|MyKM7:TR?=	M3HLV3NCVkeHUh?=
HUTU-80	M{XnZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MoDmTWM2OD1{MT60N\|M3KM7:TR?=	NGf4OZlUSU6JRWK=
NCI-H1975	M33XSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MmDtTWM2OD1{MT60OlEh\|ryP	MmH4V2FPT0WU
GAK	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlPYTWM2OD1{MT60PVkh\|ryP	NEPMe4FUSU6JRWK=
SK-N-AS	M1L5e2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{fOW2lEPTB;MkGuOVYyQSEQvF2=	Ml;6V2FPT0WU
OE33	NXvGfnN5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3ftN2lEPTB;MkGuOlA1PiEQvF2=	NI\xOI1USU6JRWK=
YKG-1	M3rhemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWjJR\|UxRTJzLk[1OFUh\|ryP	MlzpV2FPT0WU
CAL-85	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVTJR\|UxRTJzLkmzNFUh\|ryP	NI\CZ3hUSU6JRWK=
NCI-H2347	MlGwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWOzbZJnUUN3ME2yNU46PDJ6IN88US=>	M1Tid3NCVkeHUh?=
PANC-08-13	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4L6fWlEPTB;MkKuNFEyQSEQvF2=	MWTTRW5ITVJ?
SK-N-FI	NELtXmVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnzNTWM2OD1{Mj6zNFc1KM7:TR?=	MUXTRW5ITVJ?
NEC8	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NEn6UpFKSzVyPUKyMlUxPzhizszN	NFz4dIxUSU6JRWK=
AN3-CA	NWjodHZmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFPxZVdKSzVyPUKyMlYxQDRizszN	M1rldnNCVkeHUh?=
HuO9	Mn\GS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NF23dYpKSzVyPUKyMlc{QTZizszN	NVnLW5BwW0GQR1XS
COLO-800	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnHHTWM2OD1{Mj63OlU{KM7:TR?=	MXrTRW5ITVJ?
HT-29	M1jDdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NIXtOY1KSzVyPUKyMlg5OjNizszN	MWHTRW5ITVJ?
OC-314	M1;UNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYjJR\|UxRTJ{Lki4OFUh\|ryP	MVLTRW5ITVJ?
G-401	M{X3Nmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXXHcIk3UUN3ME2yN{4xPDZ{IN88US=>	Mkf1V2FPT0WU
Saos-2	NW\QRmFVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3vQPGlEPTB;MkOuOVE5OiEQvF2=	MmrEV2FPT0WU
UACC-62	M2XCSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYrJR\|UxRTJ\|LkW4N\|Mh\|ryP	NXjXSWN6W0GQR1XS
D-247MG	M{XxXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MkjITWM2OD1{Mz63PVM6KM7:TR?=	MUTTRW5ITVJ?
COLO-741	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3\KW2lEPTB;MkOuPVU3PSEQvF2=	MoP4V2FPT0WU
ES3	NGXJU5lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2DhZWlEPTB;MkSuNFAzOyEQvF2=	NVPBbpBJW0GQR1XS
LNCaP-Clone-FGC	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MoH0TWM2OD1{ND6wNlEyKM7:TR?=	NIPIUYVUSU6JRWK=
SW1710	MlTwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFz2U3ZKSzVyPUK0MlE2ODZizszN	NHXO[m5USU6JRWK=
LU-99A	NHf2UHBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYnRVVU6UUN3ME2yOE4yQDRzIN88US=>	NEPuPXZUSU6JRWK=
HOP-92	Mn;BS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NEW0W2pKSzVyPUK0MlczPSEQvF2=	NHLvcG9USU6JRWK=
LS-123	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MoG1TWM2OD1{ND65OlE1KM7:TR?=	NUHzPXdtW0GQR1XS
T84	M4TxO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXmzWIhJUUN3ME2yOE46PzZ3IN88US=>	MYnTRW5ITVJ?
HCT-116	NWjrbmdpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYHJR\|UxRTJ3LkSxPFYh\|ryP	Ml\sV2FPT0WU
M14	MmPoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{HTeGlEPTB;MkWuOFQ1PyEQvF2=	M1vi[XNCVkeHUh?=
OCUB-M	NGHGNlZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWLJR\|UxRTJ3LkS0OVYh\|ryP	NVrSVIRDW0GQR1XS
MKN45	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlTqTWM2OD1{NT62N\|E2KM7:TR?=	MV\TRW5ITVJ?
LCLC-97TM1	Mmn6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4DxWmlEPTB;MkWuO\|I5PSEQvF2=	MXXTRW5ITVJ?
RVH-421	Ml:1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M33vcWlEPTB;MkWuPFE3OSEQvF2=	NH;t[FlUSU6JRWK=
NKS-81-FD	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXPJR\|UxRTJ3LkmwNlEh\|ryP	NILPW4ZUSU6JRWK=
NCI-H596	NVLjOVlUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFXt[WFKSzVyPUK2MlA1QDdizszN	Mn;MV2FPT0WU
GB-1	NVfrOGRGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHK2XGxKSzVyPUK2MlE5PzlizszN	NVK1WWk3W0GQR1XS
ZR-75-30	NH\pNopIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnTBTWM2OD1{Nj6yNlk4KM7:TR?=	MX\TRW5ITVJ?
U-2-OS	M1XQOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFjv[JZKSzVyPUK2MlM4PTdizszN	MYPTRW5ITVJ?
HuP-T3	NWCycWJiT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MUfJR\|UxRTJ4Lk[xNFIh\|ryP	M{XhSnNCVkeHUh?=
MOLT-16	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnTVTWM2OD1{Nj62NVY3KM7:TR?=	MYjTRW5ITVJ?
U-87-MG	NGHCbotIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWXzOZVrUUN3ME2yOk44PDN6IN88US=>	M{PmeHNCVkeHUh?=
8505C	NEXM[YlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NEO1TVJKSzVyPUK2MlkyOjZizszN	M{joOXNCVkeHUh?=
SK-MEL-3	NV7JN5ZvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MkK0TWM2OD1{Nj65PFI5KM7:TR?=	NWLPUGhWW0GQR1XS
COLO-824	NUnwW3RnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYHJR\|UxRTJ5LkKxPVUh\|ryP	MXPTRW5ITVJ?
EW-1	MlrxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1nYb2lEPTB;MkeuN\|U2PCEQvF2=	MWTTRW5ITVJ?
UACC-257	M4n5dGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MlfzTWM2OD1{Nz6zPFA1KM7:TR?=	MnL3V2FPT0WU
Hs-578-T	M4LVSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1\5[GlEPTB;MkeuOVI6QSEQvF2=	NFTBfGtUSU6JRWK=
UACC-893	NIPjT21Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MUDJR\|UxRTJ5Lk[2N\|Eh\|ryP	NUXVc2RyW0GQR1XS
MHH-NB-11	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M37SR2lEPTB;MkeuPFAxPyEQvF2=	M2PCdXNCVkeHUh?=
KYSE-410	M3rEW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3jnWGlEPTB;MkiuNlc4QSEQvF2=	MYTTRW5ITVJ?
SF126	M1:yTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2S2XGlEPTB;MkiuO\|Q{PSEQvF2=	NW\pRnhUW0GQR1XS
HT-144	Ml;5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{XDNWlEPTB;MkmuN\|M3OiEQvF2=	M{e1WnNCVkeHUh?=
SW1573	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWDJR\|UxRTJ7LkO1NFkh\|ryP	MXzTRW5ITVJ?
SW620	M1u3Umdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWXJR\|UxRTJ7LkO2OFEh\|ryP	NVrKS4R7W0GQR1XS
SCH	M2POTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXPJR\|UxRTJ7Lki4N\|Eh\|ryP	NXfsNFlPW0GQR1XS
EW-22	MonJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MmeyTWM2OD1\|MD6xPVY6KM7:TR?=	Mn7OV2FPT0WU
H4	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MUHJR\|UxRTNyLkS2OVQh\|ryP	MVvTRW5ITVJ?
CAS-1	NFzZeWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmLYTWM2OD1\|MD63PFU6KM7:TR?=	NFK0XJJUSU6JRWK=
MG-63	NYS3fYJHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlfPTWM2OD1\|MD64OFc5KM7:TR?=	NEjjPZhUSU6JRWK=
MDA-MB-415	MkP3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVLGNVREUUN3ME2zNU4yPzV\|IN88US=>	NEf4R4VUSU6JRWK=
NCI-H1395	M1naRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXLJR\|UxRTNzLkKzNlgh\|ryP	NGq3fmhUSU6JRWK=
Ca-Ski	M3SzU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MX7JR\|UxRTNzLkOxO\|ch\|ryP	MWHTRW5ITVJ?
BxPC-3	M2HPZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXf2PY1rUUN3ME2zNU4{PzJ7IN88US=>	NFK0Z5FUSU6JRWK=
A3-KAW	M3X6PGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXPJR\|UxRTNzLkS0O\|Eh\|ryP	MkTlV2FPT0WU
T-24	NELzNXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYKxSWluUUN3ME2zNU44OzZ{IN88US=>	NYnGV2VXW0GQR1XS
NCI-H2029	M2e5fGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYCxboRMUUN3ME2zNU44PzZ3IN88US=>	NYHBbZFZW0GQR1XS
YAPC	NXz3OFJjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3jscGlEPTB;M{KuNFQxPyEQvF2=	NULQdFlGW0GQR1XS
SK-MEL-2	Mo\uS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVjjcWhxUUN3ME2zNk4xPTJizszN	NI\1cGFUSU6JRWK=
LS-513	NETsRXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NUWzTnNFUUN3ME2zNk4yOTh5IN88US=>	MWnTRW5ITVJ?
AsPC-1	M2PsdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MUnJR\|UxRTN{LkO2NFUh\|ryP	M1jsWXNCVkeHUh?=
KYSE-150	MlGxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mn7pTWM2OD1\|Mj6zO\|c{KM7:TR?=	MlP1V2FPT0WU
NCI-H520	Mnq0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1;ENGlEPTB;M{KuOFQ5OiEQvF2=	MWrTRW5ITVJ?
JEG-3	NHjNPIRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnHpTWM2OD1\|Mz6wPVcyKM7:TR?=	Mnq3V2FPT0WU
GMS-10	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVLXTWQ6UUN3ME2zN{4{ODB2IN88US=>	NWHQU\|ZZW0GQR1XS
HT-1080	NGj0XWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3z6U2lEPTB;M{OuN\|kh\|ryP	MVrTRW5ITVJ?
NCI-H1651	NHjh[49Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mk[wTWM2OD1\|Mz6zPVYh\|ryP	MmGxV2FPT0WU
NCI-H2122	M2T1SGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHnP[mdKSzVyPUOzMlU2PzRizszN	NGHjOnRUSU6JRWK=
ES5	MnjiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXqyd2lXUUN3ME2zN{44Ojl{IN88US=>	NV;NUHRVW0GQR1XS
8305C	NHrPNHZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVzJR\|UxRTN\|Lkm5N\|ch\|ryP	NXvTXllsW0GQR1XS
KM12	NWHKXZZsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlHyTWM2OD1\|ND6wOFc5KM7:TR?=	NEjLbI9USU6JRWK=
HCT-15	NGP1XYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWTJR\|UxRTN2LkGyO{DPxE1?	M1zJXXNCVkeHUh?=
OVCAR-5	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NI\1cJpKSzVyPUO0MlIyQDJizszN	Ml7wV2FPT0WU
NCI-H2291	NVm4RoVrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NF25fWlKSzVyPUO0MlI1PzJizszN	MV;TRW5ITVJ?
CP50-MEL-B	NVLoZoVVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWDJR\|UxRTN2Lk[1PVIh\|ryP	MWLTRW5ITVJ?
C-33-A	NWTsUGFFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2PUe2lEPTB;M{SuOlg2PyEQvF2=	NWPnOFcyW0GQR1XS
NCI-H2452	M{TzUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NI\lb3dKSzVyPUO0Mlc5QDJizszN	M3vENnNCVkeHUh?=
MDA-MB-157	M1jkN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVzJR\|UxRTN2LkixPVMh\|ryP	MWHTRW5ITVJ?
LN-405	M1TPfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFvyWlhKSzVyPUO1MlQ{ODhizszN	MlvhV2FPT0WU
MDA-MB-231	NGDQcpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4S1TGlEPTB;M{WuOVA2PCEQvF2=	MkfBV2FPT0WU
EW-24	MnW0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3LuRWlEPTB;M{WuOlM{PSEQvF2=	NYrGcml3W0GQR1XS
MKN28	MlrBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFPhdHNKSzVyPUO1MlgzOzZizszN	MXvTRW5ITVJ?
KINGS-1	MlH3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVvJR\|UxRTN3Lki0N\|Qh\|ryP	NGXGV3pUSU6JRWK=
LC-2-ad	NX;5UFlLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{HkZWlEPTB;M{[uOlk6KM7:TR?=	M1H4[nNCVkeHUh?=
IGR-1	M1W5dWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MUPJR\|UxRTN4LkewO\|Uh\|ryP	NHLvZnhUSU6JRWK=
SW626	NF[yS4dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NV7wVJU6UUN3ME2zO{4xPDF5IN88US=>	NYDIdZI5W0GQR1XS
ONS-76	NWHJUnVPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Ml\oTWM2OD1\|Nz6xN\|A6KM7:TR?=	NWjjUHNoW0GQR1XS
T98G	MnjjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHXkTWFKSzVyPUO3Mlg3OzVizszN	M4\KRXNCVkeHUh?=
NB14	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4rMe2lEPTB;M{iuOFU1PCEQvF2=	NH3kR3pUSU6JRWK=
D-423MG	MnrGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NV34NJdQUUN3ME2zPE41QDZ7IN88US=>	NVzyUYtEW0GQR1XS
NCI-H510A	NFnDc21Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MX;JR\|UxRTN6Lk[0OVEh\|ryP	NFWyUmFUSU6JRWK=
NMC-G1	M{XV[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2D6VmlEPTB;M{iuO\|IzOiEQvF2=	MknhV2FPT0WU
SW948	M3fGfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGfpNFJKSzVyPUO4Mlg6PDlizszN	MWDTRW5ITVJ?
MFM-223	NXXw[Gp6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXHJR\|UxRTN6Lkm0N\|Eh\|ryP	MVTTRW5ITVJ?
PAN1	NX6xU4JTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHjPeVNKSzVyPUO4Mlk6OTlizszN	NFTqRoFUSU6JRWK=
MZ7-mel	Mnj0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHe3OJRKSzVyPUO5MlEyQTlizszN	M1e2TXNCVkeHUh?=
COLO-679	M4nNcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1TUPWlEPTB;M{muPVcxQCEQvF2=	NF3PZ5dUSU6JRWK=
SW872	MnPQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NUfBdnlGUUN3ME20NE4zODNzIN88US=>	MXLTRW5ITVJ?
HT-1197	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1\DPGlEPTB;NECuNlg3QSEQvF2=	NGHkSnNUSU6JRWK=
ES6	NFPHNGtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2rtVGlEPTB;NECuOFU2OiEQvF2=	NWPiUZlqW0GQR1XS
SNU-387	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NV\OeY5oUUN3ME20NE45OjN6IN88US=>	Ml;tV2FPT0WU
T47D	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4DYVGlEPTB;NEGuNFE6OiEQvF2=	M3G4R3NCVkeHUh?=
G-402	MorTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NUHXVJl[UUN3ME20NU4xQDB7IN88US=>	NUHFbmZZW0GQR1XS
MZ1-PC	M4j2cGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXjJR\|UxRTRzLkixJO69VQ>?	MmDhV2FPT0WU
SW1417	NFXxWYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2L0NmlEPTB;NEKuN\|A{KM7:TR?=	MkO1V2FPT0WU
RERF-LC-MS	NW\WTZBjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NEezdnZKSzVyPUSyMlUxQDdizszN	MlvyV2FPT0WU
SF539	NHzjW5FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVToSYxvUUN3ME20Nk42PTJ7IN88US=>	MYrTRW5ITVJ?
ESS-1	MoX1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVnwWnNWUUN3ME20N{42PTV6IN88US=>	NIjMZYtUSU6JRWK=
RO82-W-1	M164c2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MUDJR\|UxRTR\|Lk[xOVMh\|ryP	MYnTRW5ITVJ?
S-117	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MoHTTWM2OD12Mz62PVU5KM7:TR?=	MmOxV2FPT0WU
SW756	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4Oz[2lEPTB;NEOuPFI1OiEQvF2=	M4\wOnNCVkeHUh?=
CP66-MEL	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2LofGlEPTB;NEWuO\|E1OyEQvF2=	NGrKc4lUSU6JRWK=
H-EMC-SS	Mn;xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NIrBNVdKSzVyPUS1Mlc3QTNizszN	MnG3V2FPT0WU
NCI-H2052	M1fHVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFLaZ3NKSzVyPUS1MlkxOjdizszN	MojxV2FPT0WU
SW684	NX3F[Yt4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnLSTWM2OD12Nz6wNFgyKM7:TR?=	NYfFdnk{W0GQR1XS
HCC1569	Mn7mS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{TEXGlEPTB;NEeuNVY2QCEQvF2=	MYPTRW5ITVJ?
KGN	NXfiboFET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3q3SmlEPTB;NEeuN\|MyOSEQvF2=	MV;TRW5ITVJ?
LCLC-103H	MnztS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mn\0TWM2OD12Nz60OFA1KM7:TR?=	MWLTRW5ITVJ?
SW780	MoXnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MlrKTWM2OD12Nz62N\|UyKM7:TR?=	MlfnV2FPT0WU
NCI-H1703	MorPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MUjJR\|UxRTR6LkOzOVIh\|ryP	NELUNWFUSU6JRWK=
HCC1395	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVzJR\|UxRTR6Lke0N\|Ih\|ryP	NHP0TIxUSU6JRWK=

... Click to View More Cell Line Experimental Data

体内研究

Gefitinib 作用于无胸腺裸鼠，抑制SKOV3 或MDA-MB-231 肿瘤生长。Gefitinib高效作用于两种类型肿瘤。处理14天后，MDA-MB-231肿瘤和SKOV3肿瘤生长抑制分别为71%和32%。

细胞实验：^[1]	+ 展开 Cell lines: NR6, NR6M 和 NR6W 细胞 Concentrations: 0 μM -2 μM Incubation Time: 72 小时 Method: 呈指数生长的细胞，包括 NR6, NR6M, NR6M和NR6W细胞按6倍接种在96孔板上，每孔为2000个细胞, 粘附，随后在PBS 中清洗，然后在含0.5% FCS的培养基上温育过夜。使用不同浓度(0-2 μM) Gefitinib或溶质对照DMSO 和EGF 处理细胞。诱导NR6wtEGFR和NR6W 细胞增殖的EGF最佳浓度已经测定，因此NR6wtEGFR和 NR6W 细胞中分别加入10 nM和 0.1 nM EGF。NR6 和NR6M细胞中不加入EGF。72 小时后，通过MTT 增殖检测测量细胞数。 (Only for Reference)
动物实验：^[3]	+ 展开 Animal Models: 携带 SKOV3或MDA-MB-231肿瘤的无胸腺裸鼠 Formulation: 0.2% DMSO Dosages: 75 mg/kg Administration: 饲喂处理 (Only for Reference)

参考文献

+ 展开

溶解度 (25°C)

体外	DMSO	89 mg/mL (199.14 mM)
	Ethanol	4 mg/mL (8.95 mM)
	Water	Insoluble
体内	从左到右依次将纯溶剂加入产品，现配现用(数据来自Selleck实验检测而非文献)： 1% CMC Na	30mg/mL

* 溶解度检测是由Selleck技术部门检测的，可能会和文献中提供的溶解度有所差异，这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据 Download Gefitinib (ZD1839) SDF

分子量	446.90
化学式	C₂₂H₂₄ClFN₄O₃
CAS号	184475-35-2
稳定性	3 years -20°C powder
稳定性	2 years -80°C in solvent
别名	N/A

计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系，公式为:

质量 (g) = 浓度 (mol/L) x 体积 (L) x 分子量 (g/mol)

摩尔浓度计算公式

质量

浓度

体积

分子量
=

×

×

*在配置溶液时，请务必参考Selleck产品标签上、MSDS / COA（可在Selleck的产品页面获得）批次特异的分子量使用本工具。

稀释计算器

用本工具协助配置特定浓度的溶液，使用的计算公式为：

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入输出 )

C1

V1

C2

V2
×

=

×

在配置溶液时，请务必参考Selleck产品标签上、MSDS / COA（可在Selleck的产品页面获得）批次特异的分子量使用本工具。.

连续稀释计算器方程

连续稀释
初始浓度:
稀释倍数:

计算结果

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

分子量计算器

通过输入化合物的化学式来计算其分子量：

注：化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量	浓度	体积	分子量
=	×	×
计算

临床试验信息 (data from https://clinicaltrials.gov, updated on 2019-03-27)

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT03866499	Not yet recruiting	NSCLC	Beta Pharma Inc.	May 2019	Phase 3
NCT03866499	Not yet recruiting	NSCLC	Beta Pharma Inc.	May 2019	Phase 3
NCT03787992	Not yet recruiting	Locally Advanced or Metastatic EGFR Sensitising Mutation Positive Non-small Cell Lung Cancer	Allist Pharmaceuticals Inc.	April 1 2019	Phase 3
NCT03787992	Not yet recruiting	Locally Advanced or Metastatic EGFR Sensitising Mutation Positive Non-small Cell Lung Cancer	Allist Pharmaceuticals Inc.	April 1 2019	Phase 3
NCT03766490	Not yet recruiting	Non-Small-Cell Lung	The First Affiliated Hospital of Soochow University\|The First People''s Hospital of Changzhou\|Second Affiliated Hospital of Soochow University\|Nantong University\|Affiliated Hospital of Jiangnan University\|Jiangyin People''s Hospital\|Changzhou No.2 People''s Hospital\|Chia Tai Tianqing Pharmaceutical Group Co. Ltd.	March 30 2019	Not Applicable
NCT03856697	Not yet recruiting	Advanced Non-small Cell Lung Cancer	Hangzhou ACEA Pharmaceutical Research Co. Ltd.\|Guangdong Provincial People''s Hospital	March 2019	Phase 3

技术支持

在订购、运输、储存和使用我们的产品的任何阶段，您遇到的任何问题，均可以通过拨打我们的热线电话400-668-6834，或者技术支持邮箱tech@selleck.cn，直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题，请给我们留言。

常见问题及建议解决方法

问题 1：
I try to dissolve Gefitinib (ZD1839) in 0.5% methylcellulose+0.2% Tween 80 for in vivo experiments. However, when I prepare the mixture, it forms precipitates. Exists another way to dissolve completely the compound?
回答：
S1025 can be dissovled in both 5% DMSO+corn oil and 5% DMSO+30% PEG 300+5% Tween 80+ddH2O at 2.5 mg/ml clearly. It dissolves in DMSO not readily, please sonicate and warm it in water bath at about 45 degree, and dissolve it clearly first. Then add other solvent.

EGFR Signaling Pathway Map

EGFR Inhibitors with Unique Features

泛EGFR抑制剂

AZD8931 (Sapitinib) : Pan-ErbB inhibitor, EGFR/ErbB2/ErbB3, IC50=4 nM/3 nM/4 nM.
活性最高的EGFR抑制剂

Afatinib (BIBW2992) : EGFR(wt), IC50=0.5 nM; EGFR(L858R), IC50=0.4 nM; EGFR(L858R/T790M), IC50=10 nM; HER2, IC50=14 nM.
FDA批准的EGFR抑制剂

Lapatinib : Approved by FDA for breast cancer.
最新的EGFR抑制剂

CO-1686 (AVL-301) ^New : Irreversible, mutant-selective EGFR inhibitor with K_i of 21.5 nM and 303.3 nM for EGFRL858R/T790M and EGFRWT, respectively.

研究领域

产品类型

Gefitinib (ZD1839)

客户使用Selleck该产品发表文献98篇：

客户使用该产品的14个实验数据：

产品安全说明书

EGFR抑制剂选择性比较

生物活性

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

参考文献

溶解度 (25°C)

化学数据 Download Gefitinib (ZD1839) SDF

计算器

摩尔浓度计算器

质量 (g) = 浓度 (mol/L) x 体积 (L) x 分子量 (g/mol)

摩尔浓度计算公式

稀释计算器

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

连续稀释计算器方程

连续稀释

计算结果

分子量计算器

总分子量：g/mol

摩尔浓度计算器

临床试验信息 (data from https://clinicaltrials.gov, updated on 2019-03-27)

技术支持

常见问题及建议解决方法

EGFR Signaling Pathway Map

EGFR Inhibitors with Unique Features

相关EGFR产品